Leicestershire Traffic Light System
View classifications| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| 5-AMINOLAEVULINIC ACID GEL (Ameluz®) | Black | Actinic keratosis | |
| ABACAVIR / LAMIVUDINE (Kivexa®) | Red | ||
| ABACAVIR/DOLUTEGRAVIR/LAMIVUDINE (Triumeq®) | Red | HIV | |
| ABATACEPT | Red | Rheumatoid arthritis |
In line with NICE TA 195 and NICE TA 280 |
| ABATACEPT | Red | Juvenile idiopathic arthritis |
In line with NICE TA 373 |
| ABIRATERONE | Red | ||
| ACAMPROSATE | Amber Simple | Alcohol dependence | |
| ACENOCOUMAROL | Green | Anticoagulation |
For patients currently being treated with phenindione. |
| ACENOCOUMAROL | Red | Anticoagulation |
New patients only. |
| ACETYLCYSTEINE (UPDATED) | Black | Respiratory disorders |
Click on drug name for further details
|
| ACETYLCYSTEINE 10% preservative free eye drops | Amber Simple | Ocular lubricants |
|
| ACITRETIN | Red | ||
| ACLIDINIUM / FORMOTEROL INHALER (Duaklir Genuair®) | Green | COPD |
LABA/LAMA combination product – to be used in line with updated COPD Guidelines |
| ACLIDINIUM INHALER 322 micrograms | Green | COPD |
For patients that cannot manage tiotropium handihaler |
| ACTIKERALL | Green | Actinic keratoses | |
| Actipatch® (NEW) | Black | Joint and muscle pain | |
| ADALIMUMAB | Red | Rheumatoid and psoriatic arthritis; ankylosing spondylitis; refractory Crohn's disease |
Added indication: Refractory Crohn’s disease |
| ADALIMUMAB (NEW) | Red | Juvenile idiopathic arthritis |
In line with NICE TA 373 |
| ADALIMUMAB | Red | Psoriasis |
In line with NICE TA 146 |
| ADALIMUMAB | Red | Hidradenitis suppurativa |
In line with NICE TA 392 |
| ADALIMUMAB | Red | Moderate to severe ulcerative colitis |
In line with NICE TA 329 |
| ADALIMUMAB | Red | Plaque psoriasis in children |
In line with NICE TA 455 |
| ADALIMUMAB | Red | Behcet’s disease |
Alternative to infliximab once established on therapy. |
| ADALIMUMAB (NEW) | Red | Non-infectious uveitis |
In line with NICE TA 460 |
| ADAPALENE / BENZOYL PEROXIDE (Epiduo®) | Green | Acne vulgaris | |
| Adios® | Black | Herbal slimming aid | |
| ADVASIL CONFORM® | Amber Simple | Hypertrophic Scars |
Includes: Kelocote®, Pro-Sil®, Cica-Care®, Advasil Conform® and Mepiform® |
| AFATINIB | Red | ||
| AFLIBERCEPT (Eylea®) (UPDATED) | Red | Wet age related macular degeneration. Diabetic macular oedema. Macular oedema due to central retinal vein occlusion and branch retinal vein occlusion. Choroidal neovascularisation. |
In line with NICE TA294, NICE TA346, NICE TA305, NICE TA409, NICE TA486 |
| Age-Related Macular Degeneration - Dietary Supplements | Black | Age-related macular degeneration (AMD) |
Not approved by local committee |
| AGOMELATINE | Amber Full SCA | Depression | |
| ALBIGLUTIDE (Eperzan®) | Black | Type 2 diabetes |
Not yet reviewed |
| ALEMTUZUMAB | Red |
Relapsing, remitting multiple sclerosis |
In line with NICE TA 312 |
| ALENDRONIC ACID | Green | Osteoporosis |
In line with NICE TA 464 |
| ALENDRONIC ACID + VITAMIN D | Black | Postmenopausal osteoporosis | |
| ALENDRONIC ACID EFFERVESCENT TABLETS (Binosto®) | Green | Osteoporosis |
For patients that cannot swallow tablets. Not suitable for administration via a feeding tube. |
| ALFENTANIL | Green Conditional | Pain management in severe renal impairment for palliative care |
In line with Palliative Care Guidance only. |
| ALIMEMAZINE (UPDATED) | Green Conditional | Various |
Historic patients who have tried or not been suitable for other sedating antihistamines or melatonin. GP to continue prescribing. |
| ALIMEMAZINE (UPDATED) | Red | Various |
Historic patients who have not tried or been considered for alternatives. Patients to be reviewed by secondary care. Secondary care to prescribe if continuing treatment required. |
| ALIMEMAZINE (UPDATED) | Black | Various |
New patients. Current patients should be discussed with the prescribing specialist and not have treatment stopped abruptly without appropriate review. |
| ALIROCUMAB (Praluent®) | Red | Primary hypercholesterolaemia |
In line with NICE TA 393 |
| ALIROCUMAB (Praluent®) (NEW) | Black | Adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels |
Not yet reviewed |
| ALISKIREN | Amber Full SCA |
Hypertension |
|
| ALITRETINOIN | Red | Severe chronic hand eczema |
In line with NICE TA 177 |
| ALOGLIPTIN | Green | Type 2 diabetes | |
| ALPHA-1 ANTITRYPSIN (Respreeza®) | Black | Emphysema in adults |
Not yet reviewed |
| ALPROSTADIL cream (Vitaros®) | Black | Erectile dysfunction | |
| ALPROSTADIL uretheral sticks and injections (NEW) | Green | Erectile dysfunction |
Not prescribable under the NHS for treatment of erectile dysfunction except in men who meet the criteria listed in part XVIIIB of the Drug Tariff. The prescription must be endorsed ‘SLS’. Maximum 4 doses per month to be prescribed. |
| Alutard Bee venom ® (NEW) | Black | Preventative treatment for bee sting allergy |
Not yet reviewed |
| Alutard Wasp venom ® (NEW) | Black | Preventative treatment for wasp sting allergy |
Not yet reviewed |
| AMANTADINE | Amber Simple | Parkinson's disease |
Click on drug name for further detail |
| AMANTADINE | Amber Simple | For fatigue in Multiple sclerosis |
Amantadine for fatigue in Multiple sclerosis: prescribing notes |
| AMIFAMPRIDINE (Firdapse®) | Black | Lambert-Eaton myasthenic syndrome | |
| AMILORIDE | Amber Full SCA | Heart failure and hypertension in infants and children | |
| AMISULPRIDE | Amber Full SCA | Schizophrenia | |
| AMPHOTERICIN 0.15% preservative free eye drops | Red | ||
| ANAGRELIDE | Red | ||
| ANAKINRA (Kineret®) (UPDATED) | Red | Periodic fevers and autoinflammatory diseases |
Requested for UHL as part of NHS England commissioning policy |
| ANASTROZOLE | Amber Simple | Adjuvant therapy in early breast cancer | |
| ANASTROZOLE (NEW) | Amber Simple | Off label chemoprevention to reduce incidence of breast cancer. |
Use in line with NICE CG 164 |
| ANIDULAFUNGIN | Black | Invasive candidiasis | |
| ANTICANCER DRUGS | Red | Neoplastic disease |
Classified as BLACK or RED unless an exception for shared care (see this list). |
| ANTIPSYCHOTICS-Atypical | Amber Full SCA | All licensed indications, personality disorder | |
| ANTIRETROVIRALS | Red | HIV | |
| ANTITHROMBIN recombinant | Black | Congenital antithrombin deficiency | |
| APIXABAN | Green | Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation |
Use in line with |
| APIXABAN | Amber Simple | Treatment and secondary prevention of DVT and PE |
In line with NICE TA 341 |
| APOMORPHINE | Amber Full SCA | Parkinson's disease | |
| APRACLONIDINE | Red | Glaucoma | |
| APREMILAST (Otezla®) | Red | Psoriasis |
In line with NICE TA 419 |
| APREMILAST (Otezla®) (UPDATED) | Red | Psoriatic arthritis |
In line with NICE TA 433 |
| ARGATROBAN (Exembol®) (NEW) | Black | For anticoagulation in adult patients with heparin-induced thrombocytopenia type II. | |
| ARIPIPRAZOLE LONG-ACTING INJECTION (Abilify Maintena®) | Amber Full SCA | Maintenance treatment of schizophrenia in patients currently stabilised on oral aripiprazole | |
| ARIPIPRAZOLE oral | Amber Full SCA | Schizophrenia. Treatment and recurrence of mania. Control of agitation and disturbed behaviour in schizophrenia | |
| ASENAPINE | Black | Manic episodes of bipolar disorder. | |
| ATALUREN | Red | Duchenne muscular dystrophy |
In line with NICE HST3 |
| ATAZANAVIR | Red | ||
| ATAZANAVIR / COBICISTAT (Evotaz®) | Red | HIV infection | |
| ATOMOXETINE | Amber Full SCA | Attention deficit hyperactivity disorder (ADHD) |
Adults Children and adolescents
|
| ATOVAQUONE | Red | ||
| ATROPINE EYE DROPS | Green Conditional | Palliative care in line with guidance |
Conditional on recommendation from palliative care team. |
| AVANAFIL | Black | Erectile dysfunction |
Not yet reviewed |
| AVIPTADIL/PHENTOLAMINE intracavernosal injection (Invicorp®) (UPDATED) | Green | Erectile dysfunction | |
| AXITINIB | Red | ||
| AZATHIOPRINE | Amber Full SCA | Dermatological disease | |
| AZATHIOPRINE | Amber Full SCA | Paediatric Inflammatory Bowel Disease (Ulcerative Colitis and Crohn's Disease) |
|
| AZATHIOPRINE | Amber Full SCA | Rheumatological disease | |
| AZATHIOPRINE | Amber Full SCA | Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Disease) & Autoimmune Hepatitis | |
| AZILSARTAN | Black | Hypertension | |
| AZTREONAM | Red | Infection in cystic fibrosis | |
| BALSALAZIDE | Amber Full SCA | Ulcerative colitis | |
| BARICITINIB (Olumiant®) | Red | Moderate-to-severe rheumatoid arthritis |
In line with NICE TA 466 |
| BASILIXIMAB (Simulect®) (NEW) | Red | Immunosuppressive therapy for Kidney Transplant in Adults and Children/Young People |
In line with NICE TA 481, NICE TA 482 |
| BECAPLERMIN | Black | ||
| BECLOMETASONE DIPROPIONATE / FORMOTEROL (Fostair®) | Green |
Asthma COPD |
Prescribe in line with Adult Asthma Guideline |
| BECLOMETASONE Inhaler - CFC free | Green | Asthma |
QVAR brand recommended for adults. Clenil Modulite brand recommended only for children. |
| BEDAQUILINE | Red | Multi-drug resistant tuberculosis | |
| BELATACEPT (Nulojix®) (NEW) | Red | Immunosuppressive therapy for Kidney Transplant in Adults and Children/Young People |
In line with NICE TA 481, NICE TA 482 |
| BENRALIZUMAB (NEW) | Red | Severe Eosinophilic Asthma |
In line with NICE TA565 Implementation date 6th June 2019 |
| BETA-INTERFERON-1a (Avonex®) (NEW) | Red | Multiple sclerosis in adults |
In line with NICE TA 527 |
| BETA-INTERFERON-1a (Rebif®) (NEW) | Red | Multiple sclerosis in adults |
In line with NICE TA 527 |
| BETA-INTERFERON-1b (Betaferon®) (NEW) | Red | Multiple sclerosis in adults |
In line with NICE TA 527 |
| BETA-INTERFERON-1b (Extavia®) (NEW) | Red | Multiple sclerosis in adults |
In line with NICE TA 527 |
| BETAMETHASONE plaster (Betesil®) | Black | Inflammatory skin disorders not responding to less potent corticosteroids |
Not approved by local committee |
| BEVACIZUMAB | Red | Retinopathy of prematurity either first line or as a second line rescue treatment. | |
| BEXAROTENE | Red | ||
| BEZLOTOXUMAB (Zinplava®) | Black | Prevention of recurrence of Clostridium difficile infection |
Not yet reviewed |
| BICALUTAMIDE | Amber Simple | Prostate cancer | |
| BICTEGRAVIR, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE (Biktarvy®) (UPDATED) | Red | HIV |
As per NHSE Clinical commissioning Policy |
| BILASTINE | Black | Allergic rhinoconjunctivitis and urticaria | |
| BIMATOPROST / TIMOLOL eye drops (Ganfort®) | Green | Glaucoma |
If prescribed in line with Glaucoma Algorithm |
| BIMATOPROST / TIMOLOL preservative free eye drops (Ganfort UD®) | Green | Glaucoma |
If prescribed in line with Glaucoma Algorithm |
| BIMATOPROST preservative free eye drops | Green | Glaucoma |
If prescribed in line with Glaucoma Algorithm |
| Bio-Oil® | Black | Skincare product | |
| BIOBRAN MGN-3 | Black | Adjuvant to cancer treatment |
Cancer Research UK statement |
| BOSENTAN | Red | Pulmonary hypertension |
Specialist centres only |
| BOSUTINIB | Red | ||
| BOTULINUM TOXIN | Red | Various indications |
Policy in development |
| BOTULINUM A TOXIN | Red | Chronic migraine |
see NICE TA 260 |
| BOTULINUM A TOXIN (Dysport®) | Black |
Not yet reviewed |
|
| BOTULINUM A TOXIN (Xeomin®) | Red | As per licence | |
| BOTULINUM NEUROTOXIN TYPE A (Xeomin®) (NEW) | Red | Chronic sialorrhoea |
In line with NICE TA 605 |
| BREXPIPRAZOLE (Rexulti ®) (NEW) | Black | Antipsychotics |
LPT prescribing group have reviewed and found no significant advantages over existing formulary products |
| BRIMONIDINE CUTANEOUS GEL | Green | Facial erythema of rosacea (fixed erythema not flushing) |
Review after one month and discontinue if no benefit |
| BRINZOLAMIDE / BRIMONIDINE (Simbrinza®) eye drops | Green | Glaucoma |
If prescribed in line with Glaucoma Prescribing Algorithm |
| BRINZOLAMIDE / TIMOLOL (Azarga®) | Green | Glaucoma |
If prescribed in line with Glaucoma Prescribing Algorithm |
| BRIVARACETAM (UPDATED) | Amber Simple | Epilepsy (third line agent) | |
| BRODALUMAB (Kyntheum®) (NEW) | Red | Moderate to severe plaque psoriasis |
In line with NICE TA 511
|
| BROMOCRIPTINE (UPDATED) | Amber Simple | Hyperprolactinaemic disorders |
Annual monitoring undertaken in secondary care Primary care should be aware of fibrotic reactions |
| BUDESONIDE (1mg orodipersible tablet) (Jorveza®) (UPDATED) | Red | Eosinophilic esophagitis | |
| BUDESONIDE (Budenofalk®) | Amber Simple | Autoimmune hepatitis, Crohn's disease, ulcerative colitis | |
| BUDESONIDE / FORMOTEROL INHALER (DuoResp Spiromax®) | Green | Asthma & COPD |
Prescribe by brand as Budesonide/Formoterol devices not interchangeable. For new patients and existing patients over 18 years after a review by a healthcare professional and counselling of patient to ensure correct use of device |
| BUDESONIDE 64mcg NASAL SPRAY (Benacort®) (NEW) | Black | ||
| BUDESONIDE and FORMETEROL (Fobumix®) Easyhaler (NEW) | Green | Asthma | |
| BUDESONIDE M/R TABLETS (Cortiment®) (NEW) | Amber Simple | Ulcerative colitis |
See formulary for place in therapy |
| BUPRENORPHINE | Green | Severe pain |
including transdermal patch |
| BUPRENORPHINE PROLONGED RELEASE INJECTION (Buvidal®) (UPDATED) | Red | Substance misuse |
Turning Point are piloting this in a small number of patients. If a patient is admitted to hospital contact turning point for advice about alternatives: 0116 3732117 – Direct dial to prescribing team 0116 3732108 – Direct Dial to Clinical Admin 0330 303 6000 – Main Switchboard |
| BUROSUMAB (Crysvita®) (NEW) | Black | X-linked hypophosphataemia in children and young people |
Not yet reviewed |
| BUSERELIN (Suprecur®) | Red | IVF | |
| BUSULFAN | Red | ||
| CABERGOLINE | Black | Parkinson's disease |
Black for new patients, existing patients to remain on therapy. |
| CABERGOLINE (UPDATED) | Amber Simple | Hyperprolactinaemic disorders |
Annual monitoring undertaken in secondary care Primary care should be aware of fibrotic reactions |
| CABERGOLINE | Red | Suppression of lactation | |
| CABOZANTINIB (Cabometyx®) (NEW) | Black | Treatment of advanced renal cell carcinoma. | |
| CALCIPOTRIOL/BETAMETHASONE CUTANEOUS FOAM (Enstilar®) | Green | Psoriasis vulgaris | |
| CALCITONIN injection | Red |
New patients only |
|
| CANAGLIFLOZIN | Amber Simple | Type 2 diabetes |
Click on drug name for further details |
| CANAGLIFLOZIN | Green Conditional | Type 2 diabetes |
Conditional on prescriber being competent to select appropriate patients. |
| CANAGLIFLOZIN / METFORMIN (Vokanamet®) | Black | Type 2 diabetes |
Not yet reviewed |
| CANGRELOR (Kengrexal®) (NEW) | Red | When undergoing PCI and cannot take oral P2Y12 inhibitors | |
| CANNABIDIOL(Epidyolex®) (UPDATED) | Red | Seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in combination with clobazam |
In line with NICE TA614 and NICE TA615 |
| CANNABIS Derivative (Sativex®) | Black | Multiple sclerosis | |
| CANNABIS OIL (NEW) | Black | ALL |
Not yet reviewed |
| CAPECITABINE | Red | ||
| CAPHOSOL® | Red | Oral mucositis in head & neck cancer patients | |
| CAPLACIZUMAB (Cablivi®) (NEW) | Black | Aquired thrombotic thrombocytopenic purpura in conjunction with plasma exchange and immunosuppression in adults |
Not yet reviewed. |
| CAPSAICIN 8% patch (Qutenza®) | Red | Peripheral neuropathic pain |
Only if unresponsive to other treatments in local guidance. |
| CAPSAICIN 8% PATCH (Qutenza®) | Black | Diabetic neuropathy | |
| CAPTOPRIL | Amber Full SCA | Heart failure and hypertension in infants and children | |
| CARIPRAZINE(Reagila®) (UPDATED) | Red | Schizophrenia |
As per LPT managed requirements/protocol
|
| CASPOFUNGIN | Red | ||
| CEFEPIME (Renapime®) (NEW) | Black | Antibiotic |
Not yet reviewed |
| CEFIXIME | Green | Gonorrhoea | |
| CEFOTAXIME | Red | ||
| CEFOXITIN (Renoxitin®) (NEW) | Red | Antibiotic | |
| CEFTAROLINE | Red | Confirmed MRSA community acquired pneumonia and complicated skin and soft tissue infections |
On advice of a consultant microbiologist only |
| CEFTAZIDIME | Red | ||
| CEFTAZIDIME / AVIBACTAM (Zavicefta®) (UPDATED) | Red | As per antimicrobial advice |
Prescribe by brand to prevent confusion. |
| CEFTOBIPROLE (Zevtera®) (NEW) | Black | For Hospital and community-acquired pneumonia in adults. | |
| CEFTOLOZANE-TAZOBACTAM (Zerbaxa®) (NEW) | Red | As per antimicrobial advice | |
| CEFUROXIME 5% eye drops | Red | ||
| CELECOXIB (NEW) | Amber Simple | Inflammatory pain associated with cancer or other palliative conditions | |
| CELECOXIB (UPDATED) | Black | Pain not associated with cancer or palliative care | |
| CELECOXIB (Onsenal®) | Black | Familial adenomatous polyposis | |
| CENEGERMIN (Oxervate®) (NEW) | Black | Neurotrophic keratitis |
Not recommended in NICE TA 532 |
| CERITINIB (Zykadia®) | Black | Lung cancer |
Not yet reviewed |
| CERTOLIZUMAB PEGOL | Red | Rheumatoid arthritis |
In line with NICE TA 375 and NICE TA 415 |
| CERTOLIZUMAB PEGOL | Red | Ankylosing spondylitis and non-radiographic axial spondyloarthritis |
In line with NICE TA 383 |
| CERTOLIZUMAB PEGOL | Red | Psoriatic arthritis |
In line with NICE TA 445 |
| CERTOLIZUMAB PEGOL (Cimzia®) (NEW) | Red | Moderate to severe plaque psoriasis |
In line with NICE TA574 Implementation date 17th July 2019 |
| CETRORELIX (Cetrotide®) | Red | IVF | |
| CHLORAMBUCIL | Red | ||
| CHLORHEXIDINE 2% EYE DROPS | Black | Fungal keratitis |
Not approved by local committee |
| CHLORHEXIDINE GLUCONATE 1% cream (Eczmol®) | Green | Adjunctive therapy for decreasing bacterial load only in cases of recurrent infected atopic eczema in children. | |
| CHLORHEXIDINE GLUCONATE 1% cream (Eczmol®) | Black | Eczema and Dermatitis |
Not approved by local committee |
| CHONDROSPHERE (Spherox®) (NEW) | Red | Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee in adults |
In line with NICE TA 508
|
| CHORIONIC GONADOTROPHIN (Pregnyl®) | Red | IVF | |
| CICA-CARE® | Amber Simple | Hypertrophic Scars |
Includes: Kelocote®, Pro-Sil®, Cica-Care®, Advasil Conform® and Mepiform® |
| CICLOSPORIN OPTHALMIC EMULSION (Ikervis®) | Amber Simple | Dry eye disease |
In line with NICE TA 369 |
| CICLOSPORIN Oral | Amber Full SCA | Dermatological disease | |
| CIDOFOVIR | Red | CMV retinitis | |
| CINACALCET | Amber Full SCA | Secondary hyperparathyroidism |
Shared care request is mandatory |
| CINACALCET | Red | Primary hyperparathyroidism | |
| CINNARIZINE / DIMENHYDRINATE (Arlevert®) | Amber Simple | Dizziness in Meniere's disease |
Click on drug name for further details |
| CIPROFLOXACIN 0.2% preservative free eye drops | Red | ||
| CIPROFLOXACIN 2mg/ml ear drops (Cetraxal®) (UPDATED) | Green | Acute otitis externa |
Please see appropriate antimicrobial guidance for treatment advice in otitis externa. Antimicrobial Guidance for Primary Care |
| CIPROFLOXACIN eye ointment | Green | Eye infections |
Second-line to chloramphenicol |
| CIPROFLOXACIN HYDROCHLORIDE 3mg / FLUOCINOLONE ACETONIDE 0.25mg (Cetraxal Plus®) (NEW) | Black | Acute otitis externa (AOE). Acute otitis media in patients with tympanostomy (AOMT) |
Not yet reviewed. |
| CITALOPRAM (UPDATED) | Amber Simple | Mental health indications as per the children’s BNF for children and young people | |
| CLADRIBINE (UPDATED) | Red | Relapsing-remitting multiple sclerosis |
In line with NICE TA616 |
| Clindamycin plus tretinoin (Treclin®) | Green | Acne |
Second choice in line with local algorithm |
| CLOMIPHENE | Red | ||
| CLOZAPINE | Red |
Leicestershire Partnership Trust consultants only |
|
| CO-PROXAMOL | Black | Analgesia |
Due to safety concerns |
| Cobicistat (Tybost®) | Red | HIV infection | |
| COBICISTAT / ELVITEGRAVIR / EMTRICITABINE / TENOFOVIR (Stribild) | Red | HIV | |
| COBIMETINIB (Cotellic®) | Black | Melanoma |
Not yet reviewed |
| COLESEVELAM | Black |
Primary and familial hypercholesterolaemia |
Not yet reviewed |
| COLESEVELAM | Amber Simple | Bile acid malabsorption |
Off label use second line to colestyramine if that is not tolerated. |
| COLESTILAN | Black | Hyperphosphataemia with renal failure |
Following local review |
| COLISTIMETHATE SODIUM (Colobreathe®) INHALATION POWDER | Red | Cystic Fibrosis | |
| COLISTIN | Red | IV for cystic fibrosis | |
| COLISTIN | Amber Full SCA |
Pseudomonas aeruginosa lung infections (Nebulised) |
Shared care request is mandatory |
| COLLAGENASE | Red | ||
| COLLAGENASE CLOSTRIDIUM HISTOLYCUM | Red | Dupuytrens |
In Line with NICE TA 459 |
| CORNEAL EPITHELIAL CELLS (Ex vivo expanded autologous human) containing stem cells (Holoclar®) | Red | Moderate-severe limbal stem cell deficiency after eye burns |
In line with NICE TA 467 |
| CRIZOTINIB | Red | ||
| CYANOCOBALAMIN (NEW) | Black | Vitamin B12 |
Initially for new patients only. Implementation date for all patients September 2020 to allow time for review. |
| CYCLOPHOSPHAMIDE | Red | ||
| DABIGATRAN (UPDATED) | Amber Simple | Venous thromboembolism (treatment and long term secondary prevention) |
In line with NICE TA 327
|
| DABIGATRAN | Green | Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation |
Use in line with |
| DABIGATRAN | Red | Prevention of Venous Thromboembolism (VTE) following knee / hip replacement surgery |
In line with NICE TA 157 |
| DABRAFENIB | Red | ||
| DACLATASVIR | Red | Hepatitis C |
In line with NICE TA 364 |
| DACLATASVIR | Red | Patients with hepatitis C who have Cirrhosis |
Reviewed by TAS |
| DACLIZUMAB | Red | Relapsing forms of multiple sclerosis |
In line with NICE TA 441 |
| DALBAVANCIN (UPDATED) | Red | Bacterial skin infections |
As per antimicrobial working party recommendations |
| DALTEPARIN | Green | Low INR |
In line with Warfarin Guidelines for Primary Care |
| DALTEPARIN (UPDATED) | Green | Thromboprophylaxis and Treatment of DVT & PE | |
| DAPAGLIFLOZIN | Amber Simple | Type 2 diabetes |
Simple amber if GP does not feel competent to initiate. Use in line with NICE TA 288 |
| DAPAGLIFLOZIN | Green Conditional | Type 2 diabetes |
Conditional on prescriber being competent to select appropriate patients |
| DAPAGLIFLOZIN (NEW) | Amber Simple | With insulin for treating Type 1 diabetes |
In line with NICE TA597 Implementation date 28th November 2019 |
| DAPAGLIFLOZIN / METFORMIN (Xigduo®) | Black | Type 2 diabetes |
Not yet reviewed |
| DAPOXETINE | Black | Premature ejaculation |
Not yet reviewed |
| DAPTOMYCIN | Red | Complicated Gram +ve skin/soft tissue infections | |
| DARBEPOETIN | Red | Anaemia of chronic kidney disease | |
| DARIFENACIN | Black | Urinary incontinence/urgency | |
| DARUNAVIR | Red | HIV infection | |
| DARUNAVIR / COBICISTAT (Rezolsta®) | Red | HIV infection | |
| DARVADSTROCEL (Alofisel®) (UPDATED) | Black | Complex perianal fistulas in adults with Crohn’s disease |
Not recommended by NICE TA 556 |
| DASABUVIR | Red | Patients with hepatitis C who have Cirrhosis |
Reviewed by TAS |
| DASATINIB | Red | ||
| DEFERASIROX | Red | Iron overload | |
| DEFERIPRONE | Red | ||
| DEGARELIX | Amber Simple | Treatment of prostate cancer | |
| DEKAS (UPDATED) | Amber Simple | Vitamin Supplement for paediatric and adult patients with cystic fibrosis | |
| DEKAS VITAMINS (various formulations) (NEW) | Black | Depending on formulation, bariatric surgery or liver disease |
Not yet reviewed |
| DENOSUMAB (Prolia®) | Amber Full SCA | Post-menopausal osteoporosis | |
| DENOSUMAB (Xgeva®) | Amber Full SCA | Prevention of skeletal related events in adults with bone metastases from solid tumours other than prostate | |
| DENOSUMAB (Xgeva®) | Red | Prevention of skeletal related events in adults with bone metastases from solid tumours other than prostate |
Red for patients with severe renal impairment (creatinine clearance less than 30ml/min) |
| DEQUALINIUM CHLORIDE VAGINAL TABLETS (Fluomizin®) | Black | Bacterial vaginosis | |
| Dermatix® | Black | Dressing for treatment of scars | |
| DERMATOPHAGOIDES PTERONYSSINUS ALLERGEN EXTRACT (Acarizax®) | Red | Immunotherapy treatment for house dust mite and allergic rhinitis. | |
| DESFERRIOXAMINE | Red | ||
| DESIRUDIN | Red | ||
| DESMOPRESSIN ORAL LYOPHILISATE (Noqdirna ®) (NEW) | Green | Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults |
To be started in primary care only. Please click drug name for more information. |
| DEXAMETHASONE intravitreal implant | Red | Non-infectious uveitis. Macular oedema due to retinal vein occlusion |
In line with NICE TA 460 |
| DEXAMFETAMINE | Amber Full SCA | Attention deficit hyperactivity disorder (ADHD) |
Adults Children and adolescents |
| DEXIBUPROFEN | Black | Pain and inflammation | |
| DEXMEDETOMIDINE (Dexdor®) (NEW) | Red | Sedation of intubated paediatric patients in an intensive care setting. | |
| DIAMORPHINE NASAL SPRAY (Ayendi®) | Black | Acute severe pain in children and adolescents |
Not yet reviewed |
| DICLOFENAC GEL 3% (Solaraze®) | Green | Actinic keratosis | |
| DIDANOSINE | Red | ||
| DIMETHYL FUMARATE | Red | Multiple sclerosis |
In line with NICE TA 320
|
| DIMETHYL FUMARATE | Red | Moderate to severe plaque psoriasis |
In line with NICE TA 475 |
| DINOPROSTONE | Red | Induction of labour | |
| DISODIUM PAMIDRONATE | Red | ||
| DISULFIRAM | Amber Simple | Adjunct in alcohol dependence | |
| DOLASETRON | Black | Chemotherapy-induced nausea & vomiting | |
| DOLUTEGRAVIR | Red | HIV | |
| DOLUTEGRAVIR WITH LAMIVUDINE (Dovato®) (NEW) | Black | HIV |
Not yet reviewed |
| DOLUTEGRAVIR/RILPIVIRINE (Juluca®) (NEW) | Black | Adult HIV treatment |
Not yet reviewed |
| DONEPEZIL (UPDATED) | Amber Simple | Alzheimer's disease |
In line with NICE NG 97 Change in traffic light status from 1st October 2018. |
| DORAVIRINE (Pifeltro®) (NEW) | Red | HIV | |
| DORIPENEM | Black | Complicated intra-abdominal and urinary tract infection | |
| DORIPENEM | Red | Hospital acquired/ventilator associated pneumonia | |
| DORNASE ALFA | Amber Simple | Cystic fibrosis | |
| DOXEPIN oral (NEW) | Red | Urticaria paediatrics |
Unlicensed |
| DOXYCYCLINE Controlled release (Efracea®) | Black | Rosacea |
Not approved by local committee |
| DOXYLAMINE SUCCINATE AND PYRIDOXINE (Xonvea®) (NEW) | Black | Nausea and vomiting in pregnancy |
Not yet reviewed |
| DRONEDARONE | Red | Atrial fibrillation |
New patients only |
| DROPERIDOL | Red | Post operative nausea & vomiting |
3rd line |
| DULAGLUTIDE | Amber Simple | Type 2 Diabetes |
If prescriber has not received specific training. |
| DULAGLUTIDE | Green Conditional | Type 2 diabetes |
Conditional on prescriber being trained to select and train patients – use in conjunction with updated NICE Clinical Guideline. Once a week preparation. |
| DULOXETINE | Green | Diabetic neuropathy |
To be used in conjunction with Neuropathic Pain Guidelines |
| DULOXETINE | Green | Stress incontinence | |
| DULOXETINE | Red | Fibromyalgia |
For use by Pain Clinic only |
| DUPILUMAB (NEW) | Red | Moderate to severe atopic dermatitis |
In line with NICE TA 534 |
| DUTASTERIDE / TAMSULOSIN (Combodart®) | Green | Benign Prostatic Hyperplasia | |
| ECULIZUMAB (Soliris ®) (NEW) | Black | Treatment of neuromyelitis optica spectrum disorder in adults who are anti-aquaporin-4 antibody-positive with a relapsing course of the disease |
Not yet reviewed |
| EDOXABAN (UPDATED) | Amber Simple | DVT and PE |
Use in line with NICE TA354
|
| EDOXABAN | Green | Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation |
Use in line with |
| EFAVIRENZ | Red | ||
| EFAVIRENZ / EMTRICITABINE / TENOFOVIR (Atripla®) | Red | ||
| EFLORNITHINE | Black | Female facial hirsuitism |
Not approved by local committee |
| ELBASVIR/GRAZOPREVIR (Zepatier) | Red | Hepatitis C |
In line with NICE TA 413 |
| ELEXACAFTOR/IVACAFTOR/TEZACAFTOR (Trikafta®) (NEW) | Red | Cystic fibrosis as part of managed access programme |
Also known as VX-445/VX-661/VX-770 |
| ELTROMBOPAG | Red | Chronic immune thrombocytopenic purpura (ITP) |
In line with NICE TA293 |
| ELUXADOLINE (Truberzi®) | Red | Irritable bowel syndrome with diarrhoea |
In line with NICE TA 471 |
| ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (Genvoya®) | Red | HIV infection | |
| EMICIZUMAB (Hemlibra®) (UPDATED) | Red | Severe congenitial haemophilia A without factor VIII inhibitors | |
| EMPAGLIFLOZIN | Amber Simple | Type 2 diabetes |
Amber if GP does not feel competent to initiate. |
| EMPAGLIFLOZIN | Green Conditional | Type 2 diabetes |
Conditional on prescriber being competent to select appropriate patients |
| EMPAGLIFLOZIN / LINAGLIPTIN (Glyxambi®) | Black | Type 2 diabetes mellitus in adults |
New formulation |
| EMPAGLIFLOZIN/METFORMIN (Synjardy®) | Black | Type 2 diabetes |
Not yet reviewed |
| EMTRICITABINE | Red | ||
| EMTRICITABINE / RILPIVIRINE / TENOFOVIR (Eviplera®) | Red | ||
| EMTRICITABINE / RILPIVIRINE / TENOFOVIR ALAFENAMIDE (Odefsey®) | Red | HIV infection | |
| EMTRICITABINE 200mg /TENOFOVIR DISOPROXIL 245mg (Ictastan®) (NEW) | Black | HIV |
Not yet reviewed. |
| EMTRICITABINE/TENOFOVIR ALAFENAMIDE (Descovy®) | Red | HIV infection | |
| ENALAPRIL | Amber Full SCA | Heart failure and hypertension in infants and children | |
| ENFUVIRTIDE | Red | ||
| ENOXAPARIN | Red | Acute coronary syndrome | |
| ENOXAPARIN (UPDATED) | Red | Thromboprophylaxis and treatment of DVT |
Courses started during the dalteparin shortage can be continued to be supplied in primary care |
| ENOXAPARIN BECAT prefilled syringes (NEW) | Black | Parenteral anticoagulant | |
| ENTACAPONE | Amber Simple | Parkinson's disease |
Click on drug name for further details |
| ENTECAVIR | Red | Chronic hepatitis B | |
| EPISIL® | Red | Oral mucositis in paediatric patients following chemotherapy | |
| EPLERENONE | Green | Post myocardial infarction with proven LVH | |
| EPOETIN DELTA | Black | Anaemia of renal failure | |
| EPOETIN intravenous | Red |
HDU |
|
| EPOETIN subcutaneous | Red | Anaemia of Chronic Kidney Disease | |
| ERDOSTEINE | Black | Mucolytic - acute exacerbation of chronic bronchitis |
Not approved by local committee |
| ERENUMAB 70mg injection (NEW) | Black | Migraine prophylaxis |
Not yet reviewed. |
| ERLOTINIB | Red | ||
| ERTAPENEM | Red | Resistant Gram negative infections (ESBL) | |
| ERTAPENEM IV | Green | Extended Spectrum Beta Lactamase (ESBL) Urinary Tract Infection (UTI) |
UTI in line with Primary care ESBL Guidance |
| ERTUGLIFLOZIN (Steglatro®) (UPDATED) | Green Conditional | Type 2 diabetes mellitus (for 18 years and over) as monotherapy |
In line with NICE TA 572 |
| ERTUGLIFLOZIN (Steglatro®) (UPDATED) | Amber Simple | Type 2 diabetes mellitus (for 18 years and over) as monotherapy or with metformin or with metformin and a dipeptidyl peptidase-4 inhibitor |
In line with NICE TA 572 and NICE TA 583 |
| ESCITALOPRAM | Black | All indications except treatment resistant depression and generalised anxiety disorder |
Not approved by local committee |
| ESCITALOPRAM | Green | Treatment resistant depression and generalised anxiety disorder | |
| ESKETAMINE HYDROCHLORIDE NASAL SPRAY (Spravato®) (NEW) | Red | In combination with a SSRI or SNRI for adults with treatment-resistant Major Depressive Disorder |
Subject to LPT Managed Entry Requirements |
| ESLICARBAZEPINE | Amber Simple | Treatment resistant epilepsy | |
| ESTRADIOL / NOMEGESTROL (Zoely®) | Black | Combined oral contraceptive | |
| ESTRAMUSTINE | Red | ||
| ETANERCEPT | Red | Juvenile idiopathic arthritis |
In line with NICE TA 373 |
| ETANERCEPT | Red | Plaque psoriasis in children |
In line with NICE TA 455 |
| ETANERCEPT | Red | DMARD for RA, including weekly SC injection | |
| ETANERCEPT | Red | Plaque psoriasis |
In line with NICE TA103 |
| ETELCALCETIDE injection (Parsabiv) | Red | Secondary hyperparathyroidism in adult patients with chronic kidney disease on haemodialysis therapy |
Inline with NICE TA 448 |
| ETHINYLESTRADIOL / DESOGESTREL (Alenvona®) | Black | Oral contraceptive |
Not yet reviewed |
| ETOPOSIDE | Red | ||
| ETRAVIRINE | Red | ||
| EVENING PRIMROSE OIL (GAMOLENIC ACID) (Epogam® or Efamast®) | Black | Cyclical breast pain/mastalgia. Atopic eczema |
No evidence to support use for these indications. |
| EVEROLIMUS | Red | Angiomyolipomas associated with tuberous sclerosis | |
| EVEROLIMUS (Certican®) | Red | Immunosuppressive therapy for Kidney Transplant in Adults and Children/Young People |
In line with NICE TA 481, NICE TA 482 |
| EVEROLIMUS (Votubia®) (NEW) | Red | Refractory focal onset seizures associated with tuberous sclerosis complex |
As per NHSE Clinical Commissioning Policy |
| EVOLOCUMAB subcutaneous injection (Repatha®) | Red | Primary hypercholesterolaemia or mixed dyslipidaemia |
In line with NICE TA 394 |
| EVRA® patch | Green | Contraception | |
| EXEMESTANE | Amber Simple | Adjuvant therapy in early breast cancer | |
| EXENATIDE (UPDATED) | Amber Simple | Type 2 Diabetes |
If prescriber has not received specific training. |
| EXENATIDE | Green Conditional | Type 2 diabetes |
Once a week preparation (Bydureon®) is formulary. Conditional on prescriber being trained to select and train patients. Use in conjunction with Updated Nice Clinical Guideline. ————————- Twice daily preparation (Byetta®) is non formulary. However, existing patients may remain on treatment |
| EZETIMIBE | Green | ||
| EZETIMIBE + SIMVASTATIN (Inegy®) | Black | Hypercholesterolaemia | |
| FAMPRIDINE | Black | Multiple Sclerosis | |
| FEBUXOSTAT | Green | Gout (2nd line after allopurinol) |
In line with NICE TA 164 |
| FENTANYL BUCCAL FILM (Breakyl®) | Black | Breakthrough cancer pain in patients already on opioids |
Not yet reviewed |
| FENTANYL BUCCAL Tablets (Effentora buccal®) (NEW) | Black | Breakthrough pain for patients with cancer |
Not yet reviewed |
| FENTANYL intranasal spray | Black | Breakthrough cancer pain | |
| FENTANYL Sublingual (Abstral®) | Green Conditional | Breakthrough cancer pain in patients already on opioids. Palliative care in line with guidance |
Conditional on recommendation from palliative care team. |
| FENTANYL TRANSDERMAL SYSTEM (IONSYS®) | Black | Post-operative pain | |
| FENTICONAZOLE | Black | Vulvovaginal candidiasis | |
| FERRIC MALTOL(Feraccru®) (NEW) | Red | Iron deficiency anaemia in IBD after at least two failed oral treatment options | |
| FERUMOXYTOL INJECTION (Rienso®) | Black | Iron deficiency anaemia in chronic kidney disease | |
| FESOTERODINE | Black | Urinary frequency | |
| FIBRINOGEN (Riastap®) (NEW) | Red | Treatment of severe bleeding in acquired hypofibrinogenemia resulting from operative interventions, in particular after cardiac surgery | |
| FIBRINOGEN CONCENTRATE (Human) (FibCLOT®) | Black | Treatment and perioperative prophylaxis of bleeding in patients with congenital hypo- or afibrinogenaemia with bleeding tendency |
New formulation |
| FIDAXOMICIN | Amber Simple |
Clostridium difficile infection |
GP can initiate if in line with Community Clostridium difficile Care Pathway |
| FILGRASTIM | Red | ||
| FINGOLIMOD | Red | Multiple Sclerosis |
NICE supported. |
| FLUDARABINE | Red | ||
| FLUNARIZINE | Red | Migraine prophylaxis in adults | |
| FLUNARIZINE | Red | Alternating hemiplegia/refractory migraine in children |
Unlicensed |
| FLUOCINOLONE ACETONIDE (Iluvien®) intravitreal implant | Red | Diabetic macular oedema |
In line with NICE TA301 |
| FLUOCINOLONE ACETONIDE INTRAVITRAL IMPLANT (Iluvien®) (NEW) | Red | Recurrent non-infectious uveitis |
In line with NICE TA590 Implementation date 31st October 2019 |
| FLUOXETINE (UPDATED) | Amber Simple | Mental health indications as per the children’s BNF for children and young people | |
| FLUPENTIXOL (oral) | Green Conditional | Schizophrenia and other psychoses |
If used for schizophrenia or psychoses to be initiated only after diagnosis and advice to use this typical antipsychotic has been discussed with specialist |
| FLUPENTIXOL DECANOATE | Amber Full SCA | Schizophrenia | |
| FLUPHENAZINE DECANOATE | Amber Full SCA | Schizophrenia | |
| FLUTICASONE / AZELASTINE NASAL SPRAY (Dymista®) | Green | Rhinitis |
To be used in line with the Allergic Rhinitis Pathway |
| FLUTICASONE / FORMOTEROL INHALER (Flutiform®) | Black | Asthma |
Reviewed by LLR Respiratory Prescribing Group. |
| FLUTICASONE / VILANTEROL INHALER (Relvar®) | Black | Asthma |
Reviewed by LLR Respiratory Prescribing Group. |
| FLUTICASONE FUROATE (Avamys®) | Green | Allergic rhinitis | |
| FLUTICASONE/ SALMETEROL XINAFOATE INHALER (AirFluSal Forspiro®) | Black | COPD and Asthma |
Reviewed by LLR Respiratory Prescribing Group. |
| FOLINIC ACID | Red | ||
| FOLLITROPHIN alfa | Red | IVF | |
| FONDAPARINUX | Red | Heparin Induced Thrombocytopenia (HIT) | |
| FOSAMPRENAVIR | Red | ||
| FOSFOMYCIN IV | Red | Only in line with advice from UHL microbiology |
Please note that there is a separate traffic light entry for oral Fosfomycin. |
| FOSFOMYCIN Oral | Green | Extended Spectrum Beta Lactamase (ESBL) Urinary Tract Infection (UTI) |
UTI in line with Primary care Multi-resistant Lower UTI Guidance. |
| FreeStyle Libre® Sensor (UPDATED) | Amber Simple | Diabetes glucose monitoring inline with NHSE criteria. |
As per LMSG freestyle libre documents An initiation letter is required for an initial six month trial. Continuation dependent on letter detailing improvement in the NHSE England parameters.
|
| FREMANEZUMAB (Ajovy ®) (NEW) | Black | Migraine prophylaxis |
Not reviewed |
| FULVESTRANT | Amber Simple | Oestrogen receptor positive metastatic or locally advanced breast cancer in post menopausal women in whom disease progresses or relapses while on or after other anti oestrogen therapy |
Secondary care will administer first three doses. |
| FUROSEMIDE | Amber Full SCA | Heart failure and hypertension in infants and children | |
| GABAPENTIN | Green | Neuropathic pain |
To be used in conjunction with |
| GALANTAMINE | Red | Alzheimer's disease |
Leicestershire Partnership Trust consultants only |
| GALCANEZUMAB (Emgality ®) (NEW) | Black | Migraine prophylaxis |
Not yet reviewed |
| GAMMAGLOBULIN | Red | ||
| GANCICLOVIR | Red | ||
| GANCICLOVIR 0.15% EYE GEL | Black | Acute herpetic keratitis |
Only GREEN whilst Aciclovir eye ointment 3% is not available. Definite diagnosis only.To be used in line with local guidance Ganciclovir 0.15% eye gel |
| GANIRELIX ACETATE (Fyremadel®) (NEW) | Red | Prevention of premature luteinising hormone (LH) surges in women undergoing ovarian stimulation for IVF | |
| GEFITINIB | Red | ||
| GENTAMICIN | Red | IV and inhalation | |
| GENTAMICIN 1.5% preservative free eye drops | Red | ||
| GLATIRAMER ACETATE (Copaxone®) (NEW) | Red | Multiple sclerosis in adults |
In line with NICE TA 527 |
| GLECAPREVIR-PIBRENTASVIR (Maviret®) (NEW) | Red | Hepatitis C |
In line with NICE TA 499 |
| GLUCODRATE® | Amber Simple | High Output Stoma (HOS) | |
| GLUCOSAMINE | Black | Osteoarthritis | |
| GLYCEROL PHENYLBUTYRATE (Ravicti®) (NEW) | Black | Chronic management of patients with urea cycle disorders (UCDs) |
Not yet reviewed |
| GLYCERYL TRINITRATE Ointment 0.4% | Green | Anal fissure | |
| GLYCOPROTEIN IIb/IIIa inhibitors | Red | ||
| GLYCOPYRRONIUM (Sialanar®) | Black | Persistent drooling in children and adolescents with neurological conditions, such as cerebral palsy, epilepsy and neurodegenerative diseases | |
| GLYCOPYRRONIUM / BECLOMETASONE / FORMOTEROL metered dose Inhaler (Trimbow®) (NEW) | Green | Maintenance of COPD. | |
| GLYCOPYRRONIUM BROMIDE oral solution 1mg/5ml | Black | Peptic ulcer (add-on therapy) |
Not yet reviewed |
| GLYCOPYRRONIUM INHALER (Seebri Breezhaler®) | Black | COPD |
Following review by LLR Respiratory Prescribing Group and Therapeutic Advisory Service |
| GLYCOPYRRONIUM LIQUID (Colonis) (NEW) | Amber Simple | Sialorrhoea in paediatrics | |
| GOLD salts | Red | Rheumatoid arthritis |
Red for new patients Full SCA to remain for existing patients |
| GOLIMUMAB | Red | Psoriatic arthritis (PA) and Rheumatoid arthritis(RA)in line with NICE guidance |
PA see NICE TA 220 |
| GOLIMUMAB | Red | Ankylosing spondylitis |
In line with NICE TA 233 |
| GOLIMUMAB | Red | Moderate to severe active ulcerative colitis |
In line with NICE TA 329 |
| GOLIMUMAB (NEW) | Red | Non-radiographic axial spondyloarthritis |
In line with NICE TA 497 |
| GONADORELIN ANALOGUES | Green | Prostate cancer |
GP can give first injection to patients in whom anti-androgen treatment has been started by secondary care clinician. |
| GONADORELIN ANALOGUES | Amber Simple | Gender reassignment |
Must be prescribed in line with recommendations from specialist. The nearest specialist is Nottingham. |
| GOSERELIN | Green | Prostatic carcinoma |
GP can give first injection to patients in whom anti-androgen treatment has been started by secondary care clinician. |
| GOSERELIN | Amber Simple | Endometriosis, uterine fibroids | |
| GOSERELIN 3.6mg (Zoladex®) | Amber Simple | Breast cancer |
Zoladex 3.6mg implant is the only licensed product for breast cancer |
| GRANISETRON | Black | Chemotherapy-induced nausea | |
| GRANISETRON oral and injection | Green Conditional | Palliative care in line with guidance |
Conditional on recommendation from palliative care team. |
| GRANISETRON patch | Black | Chemotherapy-induced nausea |
Not yet reviewed |
| GRASS POLLEN ALLERGEN EXTRACT subcutaneous injection (Pollinex®) | Red | Grass pollen allergies | |
| GRASS POLLEN ALLERGEN EXTRACT sublingual (Grazax®) | Amber Full SCA | Grass pollen allergies | |
| GUANFACINE | Amber Full SCA | ADHD - Adult |
Adult Full SCA and Request Form |
| GUANFACINE | Amber Full SCA | ADHD - Peadiatric |
Paediatric Full SCA and Request Form |
| GUSELKUMAB (UPDATED) | Red | Moderate to severe plaque psoriasis in adults |
In line with NICE TA 521.
|
| HALOPERIDOL (oral) | Green Conditional | Schizophrenia and psychoses |
If used for schizophrenia or psychoses to be initiated only after diagnosis and advice to use typical antipsychotic has been discussed with specialist |
| HALOPERIDOL DECANOATE | Amber Full SCA | Schizophrenia | |
| HEPARIN | Red | Full IV anticoagulation | |
| HEPARIN SODIUM FLUSH | Green | Flushing solution for maintenance of patency of intravenous devices | |
| HEPATITIS C treatments | Red | ||
| HERBAL MEDICINES that are unregistered | Black |
Not approved by local committee |
|
| HERBAL MEDICINES with a Marketing Authorisation | Black |
Reviewed upon request by a consultant or GP prescribing lead |
|
| HERBAL MEDICINES with a Traditional Herbal Registration | Black |
Not approved by local committee |
|
| HISTIDINE TRYTOPHAN KETOGLUTARATE MANITOL (Custodiol®) (NEW) | Red | For myocardial protection in complex cardiac surgery. For organ preservation in transplant surgery | |
| HOMEOPATHIC MEDICINES | Black | Various |
Not approved by local committee see Position Statement |
| HUMAN CYTOMEGALOVIRUS IMMUNOGLOBULIN (CMVIG) (Cytotect CP Biotest®) (NEW) | Black | Clinical manifestations of cytomegalovirus infection in patients subjected to immunosuppressive therapy |
Not yet reviewed |
| HYALURONIC ACID DERIVATIVE (Synvisc®) | Black | Black in all indications EXCEPT for pain relief in osteoarthritis of shoulder joint (RED) | |
| HYALURONIC ACID DERIVATIVE (Synvisc®) | Red | Pain relief in osteoarthritis of shoulder joint. | |
| HYDROCORTISONE (Alkindi®)(Granules in capsules for opening) | Black | Adrenal insufficiency in infants |
Not yet reviewed |
| HYDROCORTISONE 1% / OXYTETRACYCLINE 3% (Terra-Cortril®) | Black | Overgranulation of wounds |
Not approved by local committee |
| HYDROCORTISONE INJECTION | Amber Simple | Emergency HC injection kit |
Kit for patients with Addison’s disease or high risk due to long term steroid use. Dose to be recommended by specialist, normally 50 or 100mg. |
| HYDROCORTISONE modified release (Plenadren®) | Black |
Hypoadrenalism (once daily dose) |
|
| HYDROXYCARBAMIDE | Amber Full SCA | Myeloproliferative disorders | |
| HYDROXYCARBAMIDE SOLUTION (Xromi®) (NEW) | Black | Prevention of vaso-occlusive complications of Sickle Cell disease |
Not yet reviewed |
| HYDROXYCHLOROQUINE | Amber Full SCA | Rheumatological disease | |
| IBANDRONIC ACID - IV | Red | Postmenopausal osteoporosis | |
| IBANDRONIC ACID - Oral | Amber Simple | Breast cancer bone metastases | |
| IBANDRONIC ACID 50mg tablets (NEW) | Amber Simple | Prevention of mestastases in early breast cancer patients with low female sex hormones |
First three months of prescribing due to renal monitoring to be from the hospital. Stop date to be recorded as total treatment with bisphosphonate to be 36 months. Unlicensed use see NICE ES 15 for more information. |
| IBANDRONIC ACID Oral monthly | Green | Postmenopausal osteoporosis |
In line with NICE TA 464 |
| ICATIBANT acetate | Red | Hereditary angioedema | |
| IDARUBICIN | Red | ||
| IDARUCIZUMAB (Praxbind) | Red | Reversal of severe bleeding due to dabigatran | |
| IDEBENONE (Raxone®) | Black | Leber’s hereditary optic neuropathy |
Not yet reviewed |
| IDELALISIB | Red | ||
| IDURSULFASE | Black | Hunter syndrome (mucopolysaccharidosis II) | |
| IMATINIB | Red | ||
| IMIPENEM | Red | ||
| IMIQUIMOD CREAM 3.75% (Zyclara®) | Black |
Actinic keratosis of face and scalp |
|
| IMIQUIMOD cream 5% (Aldara®) | Red | Basal cell carcinoma | |
| IMIQUIMOD cream 5% (Aldara®) | Green | Actinic keratoses |
In line with Actinic Keratoses treatment pathway |
| IMMUNOGLOBULINS | Red | ||
| INDACATEROL (Breezhaler®) (UPDATED) | Black | COPD |
Reviewed by LLR Respiratory Prescribing Group, deemed not appropriate for review by TAS |
| INDACATEROL / GLYCOPYRRONIUM INHALER (Ultibro Breezhaler®) | Black | COPD |
Reviewed by LLR Respiratory Prescribing Group, deemed not appropriate for review by TAS |
| INDINAVIR | Black | ||
| INFLIXIMAB | Red | All indications | |
| INGENOL MEBUTATE GEL (Picato®) | Black |
Actinic keratosis (non hypertrophic) |
To black due to MHRA alert |
| INSULIN ASPART (Fiasp®) (UPDATED) | Green Conditional | Type 1 and 2 diabetes mellitus in adults |
Conditional on prescriber being competent to select appropriate patients. |
| INSULIN DEGLUDEC (Tresiba®) | Green Conditional | Diabetes mellitus in adults |
Conditional on prescriber being trained to select appropriate patients |
| INSULIN DEGLUDEC (Tresiba®) | Amber Simple | Diabetes mellitus in adults |
Simple amber if prescriber has not received specific training. |
| INSULIN DEGLUDEC / LIRAGLUTIDE (combination product) (Xultophy®) | Green Conditional | Diabetes |
Conditional on prescriber being trained to select and train patients. |
| INSULIN DEGLUDEC/LIRAGLUTIDE (combination product) (Xultophy®) | Amber Simple | Diabetes |
For those who have not had the training. |
| INSULIN GLARGINE (Toujeo® 300units per ml) | Green Conditional | Diabetes mellitus in adults. First line concentrated insulin of choice in insulin resistant patients requiring large amounts of insulin. Please take extra care in prescribing |
Conditional on prescriber being competent to select appropriate patients. |
| INSULIN GLARGINE / LIXISENATIDE (Suliqua®) (UPDATED) | Black | Type 2 Diabetes mellitus in combination with metformin |
New formulation |
| INSULIN GLULISINE (Apidra®) | Green Conditional | Type 1 and 2 diabetes |
Conditional on prescriber being competent to select appropriate patients |
| INSULIN LISPRO (Humalog®) U200 | Green Conditional | Diabetes Mellitus |
Conditional on prescriber being competent to select appropriate patients |
| INSULIN LISPRO (Humalog®) U200 | Amber Simple | Diabetes Mellitus |
Amber if GP does not feel competent to initiate. |
| INTERFERON ALFA | Red | ||
| INTERFERON BETA | Red | ||
| INTERFERON GAMMA (Immukin®) (NEW) | Red | For mycobacterial infections and pulmonary and miliary | |
| IRON(III) ISOMALTOSIDE 1000 (Diafer®) | Red | Iron deficiency (renal use only) | |
| ISAVUCONAZOLE | Red | Invasive aspergillosis and mucormycosis | |
| ISOTRETINOIN - Oral | Red | Severe acne | |
| ISOTRETINOIN - Topical | Green | Mild-moderate acne | |
| IVABRADINE | Green | Chronic stable angina |
For patients who cannot tolerate beta blockers |
| IVABRADINE | Amber Simple | Chronic heart failure | |
| IVACAFTOR (Kalydeco®) | Red | Cystic fibrosis |
As per NHSE policy statement |
| IVERMECTIN CREAM | Green | Moderate to severe papulo-pustula rosacea | |
| IXEKIZUMAB (NEW) | Red | Psoriatic arthritis after inadequate response to DMARDs |
In line with NICE TA 537 Implementation date 8th November 2018 |
| IXEKIZUMAB | Red | Psoriasis |
In line with NICE TA 442 |
| KELO-COTE® | Amber Simple | Hypertrophic Scars |
Includes: Kelocote®, Pro-Sil®, Cica-Care®, Advasil Conform® and Mepiform® |
| KETAMINE | Green Conditional | Palliative care in line with guidance |
Conditional on recommendation from palliative care team.
|
| KETOCONAZOLE TABLETS | Black | Fungal infections |
Risk of hepatotoxicity outweighs benefit |
| KETOPROFEN / OMEPRAZOLE (Axorid®) | Black | Pain and inflammation for patients at risk of NSAID associated ulcers | |
| KETOROLAC | Green Conditional | Palliative care in line with guidance |
Conditional on recommendation from palliative care team. |
| Klean-Prep® | Red | Bowel cleansing | |
| LACOSAMIDE | Amber Simple | Resistant epilepsy | |
| LAMIVUDINE | Red | ||
| LAMIVUDINE / ZIDOVUDINE | Red | ||
| LANADELUMAB (Takhyzro®) (NEW) | Red | Preventing recurrent attacks of hereditary angioedema |
In line with NICE TA606 |
| LANREOTIDE | Red | Neuroendocrine tumours | |
| LANREOTIDE | Red | Acromegaly |
New patients only |
| LANREOTIDE | Green Conditional | Palliative Care |
Link to Palliative Care Guidelines |
| LANTHANUM CARBONATE | Amber Simple | Hyperphosphataemia with renal failure | |
| LAPATINIB | Red | ||
| LATANOPROST preservative free eye drops | Green | Glaucoma |
If prescribed in line with Glaucoma Prescribing Algorithm |
| LECICARBON A® suppositories | Black | Laxative or bowel preparation |
Not yet reviewed |
| LEDIPASVIR/SOFOSBUVIR (Harvoni®) | Red | Hepatitis C |
In line with NICE TA 363 |
| LEFLUNOMIDE | Amber Full SCA | Rheumatological disease | |
| LENOGRASTIM | Red | ||
| LENVATINIB tablets (Kisplyx®) | Black | Renal cell carcinoma | |
| LETERMOVIR (Prevymis®) (NEW) | Red | Prevention of cytomegalovirus disease after a stem cell transplant |
In line with NICE TA591 Implementation date 31st October 2019 |
| LETROZOLE | Amber Simple | Adjuvant therapy in early breast cancer | |
| LEUPRORELIN | Amber Simple | Endometriosis, uterine fibroids | |
| LEUPRORELIN | Green | Prostate cancer (subcutaneous injection for patients at risk of haematoma) |
GP can give first injection to patients in whom anti-androgen treatment has been started by secondary care clinician. |
| LEVETIRACETAM | Green Conditional | Palliative care in line with guidance |
Conditional on recommendation from palliative care team. |
| LEVETIRACETAM - IV | Red | Epilepsy |
Restricted to patients who are already maintained on the oral preparation |
| LEVETIRACETAM - Oral | Amber Simple | Epilepsy | |
| LEVODOPA/CARBIDOPA infusion (Duodopa) | Red | Parkinson's disease |
Specialist centres only |
| LEVOFLOXACIN Eyedrops - unpreserved | Red | Bacterial keratitis | |
| LEVOFLOXACIN NEBULISER SOLUTION (Quinsair®) (UPDATED) | Red | Chronic Pseudomonas lung infection in cystic fibrosis (adults) | |
| LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (Levosert®) (UPDATED) | Green | Contraception or heavy menstrual bleeding | |
| LIDOCAINE patch | Green | Postherpetic neuralgia |
To be used in conjunction with Neuropathic Pain Guidelines |
| LIDOCAINE patch (UPDATED) | Red | Focal neuropathic pain | |
| LIDOCAINE Patch | Black | All other indications (except postherpetic neuralgia and focal neuropathic pain) | |
| LIDOCAINE/PRILOCAINE cutaneous spray (Fortacin) | Black | Primary premature ejaculation |
Not yet reviewed |
| LINACLOTIDE | Green | Moderate to severe irritable bowel syndrome with constipation | |
| LINAGLIPTIN | Green | Type 2 Diabetes | |
| LIOTHYRONINE | Red | Concomitant therapy with thyroxine |
For patients who have hypothyroidism who have had inadequate response to thyroxine alone, in line with guidance |
| LIPEGFILGRASTIM | Black |
Chemotherapy-induced neutropenia |
Not yet reviewed locally |
| LIRAGLUTIDE | Green Conditional | Type 2 diabetes |
For patients unable to tolerate lixisenatide. Conditional on prescriber being trained to select and train patients – Use in conjunction with Updated NICE Clinical Guideline |
| LIRAGLUTIDE | Amber Simple | Type 2 diabetes |
If prescriber has not received specific training.
|
| LIRAGLUTIDE (Saxenda®) | Black | Obesity in type 2 diabetes |
Not yet reviewed |
| LISDEXAMFETAMINE DIMESYLATE | Amber Full SCA | ADHD when response to methylphenidate is inadequate |
Adults Children and adolescents |
| LISINOPRIL | Amber Full SCA | Heart failure and hypertension in infants and children | |
| LITHIUM SALTS | Amber Full SCA | Mania, Bipolar Disorder, Recurrent Depression or Aggressive or Self-mutilating behaviour. | |
| LIXISENATIDE | Green Conditional | Type 2 diabetes |
Conditional on prescriber being trained to select and train patients |
| LIXISENATIDE | Amber Simple | Type 2 diabetes |
If prescriber has not received specific training. |
| LOMITAPIDE (Lojuxta®) (UPDATED) | Red | Homozygous familial hypercholesterolaemia |
Requested for UHL as part of NHS England commissioning policy. |
| LOMUSTINE | Red | ||
| LOPINAVIR / RITONAVIR (Kaletra®) | Red | ||
| LOSARTAN | Amber Full SCA | Heart failure and hypertension in infants and children | |
| LOTEPREDNOL eye drops (Lotemax®) | Red | Post-operative inflammation following ocular surgery | |
| LOXAPINE inhalation powder (Adasuve®) | Black | Rapid control of mild-moderate agitation in schizophrenia or bipolar disorder |
Not yet reviewed |
| LUBIPROSTONE (UPDATED) | Green | Chronic refractory constipation |
Discontinued in the UK for commercial reasons |
| LUMACAFTOR /IVACAFTOR (Orkambi®) | Red | Cystic fibrosis |
As per NHSE policy statement |
| LURASIDONE (UPDATED) | Black | Psychosis not associated with schizophrenia | |
| LURASIDONE | Amber Full SCA | Schizophrenia in adults aged 18 years and over unable to tolerate or non-responsive to aripiprazole. or those who are not suitable for clozapine. | |
| MacuLEH Light® | Black | Age-related macular degeneration |
Not approved by local committee see Guideline |
| MAGNESIUM ASPARTATE DIHYDRATE (Magnaspartate®) | Amber Simple | Magnesium deficiency |
Licensed preparation now available. This will be used in preference to any unlicensed preparations. |
| MANNITOL dry powder inhaler | Red | Cystic fibrosis | |
| MARAVIROC | Red | ||
| MEDROXYPROGESTERONE ACETATE DEPOT INJECTION (Sayana Press®) | Green | Long-term contraception | |
| MELATONIN | Black | Primary insomnia in adults. Circadian asynchrony in elderly institutionalised patients | |
| MELATONIN | Amber Simple | Free running circadian rhythm and delayed sleep phase syndrome |
Simple Amber only applies to Circadin m/r tablets or oral solution 5mg/5ml. Other formulations are secondary care only. |
| MELATONIN | Red | Learning disability (Adult). Huntington's disease. Parkinson's disease. | |
| MELATONIN | Red |
Acute circadian asynchrony in hospitalised patients on ITU, HDU and other care areas |
|
| MELATONIN (Colonis®) (NEW) | Black | Jet lag | |
| MELATONIN (doses of 10mg daily or less) | Amber Simple | Sleep disorders children (see comments) continued in adults if proven efficacy in childhood |
Sleep onset insomnia and delayed sleep phase syndrome. |
| MELATONIN (doses over 10mg daily) | Red | Sleep disorders children (see comments), continued in adults if proven efficacy in childhood |
Sleep onset insomnia and delayed sleep phase syndrome in children |
| MELATONIN M/R 1mg and 5mg tablets (Slenyto ®) (UPDATED) | Black | Treatment of insomnia not covered by the simple amber status | |
| MELATONIN M/R 1mg and 5mg tablets (Slenyto®) (UPDATED) | Amber Simple | Insomnia for children aged 2-18 years with Autism Spectrum Disorder and or Smith-Magenis. |
New patients only |
| MELPHALAN | Red | ||
| MEMANTINE (UPDATED) | Amber Simple | Alzheimer's disease |
in line with NICE NG 97 Change in traffic light status from 1st October 2018 |
| MENOTROPHIN (Menopur®) | Red | IVF | |
| MEPIFORM® | Amber Simple | Hypertrophic Scars |
Includes: Kelocote®, Pro-Sil®, Cica-Care®, Advasil Conform® and Mepiform® |
| MEPOLIZUMAB (Nucala®) | Red | To treat severe refractory eosinophilic asthma. |
For use by specialist respiratory clinician in line with NICE TA 431 |
| MERCAPTAMINE (Cystadrops®) | Black | Corneal cystine crystal deposits in patients aged ≥ two years with cystinosis |
New formulation |
| MERCAPTOPURINE | Amber Full SCA | Paediatric Inflammatory Bowel Disease (Ulcerative Colitis and Crohn's Disease) | |
| MERCAPTOPURINE | Red | Leukaemia | |
| MERCAPTOPURINE | Amber Full SCA | Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Disease) & Autoimmune Hepatitis | |
| MEROPENEM | Red | ||
| MESALAZINE (Mezavant® XL) | Black | Ulcerative colitis |
Not supported by local committee |
| MESALAZINE ORAL (prescribe by brand) | Amber Full SCA | Ulcerative colitis, Crohn' s disease and paediatric colitis | |
| MESALAZINE RECTAL | Amber Simple | Ulcerative colitis and Crohn's disease | |
| METHADONE | Green Conditional | Palliative care in line with palliative care guidance. |
Conditional on recommendation from palliative care team. |
| METHADONE (oral) but note NOT 10mg/1ml (NEW) | Amber Simple | Chronic pain with ongoing advice from specialist services on dose reduction | |
| METHADONE 10mg/1ml oral liquids | Black | All indications |
This is to prevent dosing errors. The 1mg/1ml oral liquid strength remains available. |
| METHOTREXATE Injection | Red | ||
| METHOTREXATE Oral | Amber Full SCA | Rheumatological disease | |
| METHOTREXATE Oral | Amber Full SCA | Dermatological disease | |
| METHOTREXATE Oral | Red | Severe refractory asthma | |
| METHOTREXATE Oral | Amber Full SCA | Crohn's Disease | |
| METHYLNATREXONE | Green Conditional | Palliative care in line with guidance. |
Conditional on recommendation from palliative care team. |
| METHYLPHENIDATE | Green Conditional | Palliative care in line with guidance |
Conditional on recommendation from palliative care team. |
| METHYLPHENIDATE (+'CR') | Amber Full SCA | Attention deficit hyperactivity disorder (ADHD)- prescribe CR formulation by brand name only |
For information about products please see relevant Shared Care. |
| MEXILETINE | Red | Ventricular arrhythmia |
New patients. Existing prescribing in primary care to continue. |
| MEXILETINE (Namuscla®) (NEW) | Black | Symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders |
Not yet reviewed |
| MIANSERIN (UPDATED) | Amber Simple | Depression |
Mianserin is simple amber once the specialist has prescribed and monitored FBC for the first three months. After this time there are no on-going monitoring requirements but treatment should be stopped and a full blood count obtained if fever, sore throat, stomatitis, or other signs of infection develop. Seek advice from specialist in this scenario. |
| MIDAZOLAM (Buccolam®) | Amber Simple | Status epilepticus | |
| MIDAZOLAM buccal | Green Conditional | Palliative care in line with guidance. |
Conditional on recommendation from palliative care team. |
| MIDODRINE | Amber Simple | Severe orthostatic hypotension |
Licensed product now available |
| MIDOSTAURIN (Rydapt®) (NEW) | Black | Newly diagnosed FLT3 mutation-positive acute myeloid leukaemia, aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, or mast cell leukaemia. | |
| MIFEPRISTONE | Red | ||
| MIGLUSTAT | Black | Niemann-Pick type C disease | |
| MIRABEGRON | Green | Symptoms of urinary frequency, urgency and urge incontinence |
In line with Overactive Bladder Pathway |
| MITOTANE | Red | ||
| MODAFINIL | Amber Full SCA | Daytime sleepiness associated with Narcolepsy and existing patients being treated for Daytime Sleepiness associated with Obstructive Sleep Apnoea Syndrome, Idiopathic Hypersomnia & Shift Work Sleep Disorder. | |
| MOLLUDAB® | Black |
Molluscum contagiosum |
Not yet reviewed. |
| MOLOGRAMOSTIN | Red | ||
| MOLUTREX® | Black | Molluscum contagiosum |
Not yet reviewed |
| MOVICOL liquid® | Black | Constipation | |
| MOVICOL® ready to take solution in sachet | Black | Constipation |
Not yet reviewed |
| Moviprep® | Red | Prior to endoscopy |
3rd line if intolerant to Klean Prep® |
| MOXIFLOXACIN | Red | Multi-drug resistant tuberculosis | |
| MOXIFLOXACIN | Black | Respiratory tract infections (general) | |
| MUCODIS® | Red | Oral mucositis in head & neck cancer patients | |
| MYCOPHENOLATE | Red | Interstitial lung diseases (Connective tissue disease related ILD) unresponsive to other immunosuppressives. | |
| MYCOPHENOLATE (UPDATED) | Amber Full SCA | Immunosuppression following renal transplantation |
Exception agreed to red status: Full shared care to allow GPs to continue supplying to historical patients still on shared care where appropriate for patient and the GP agrees. |
| MYCOPHENOLATE (NEW) | Red | Immunosuppression following renal transplantation | |
| MYCOPHENOLATE MOFETIL | Red | Specialist rheumatology prescribing for severe lupus, severe polymyositis or systemic vasculitis | |
| MYCOPHENOLATE MOFETIL | Red | Specialist heamatology use in graft versus host disease in bone marrow transplant | |
| NABILONE | Black | Chemotherapy induced nausea and vomiting | |
| NALDEMEDINE TOSYLATE(Rizmoic®) (NEW) | Black | opioid-induced constipation |
Not yet reviewed |
| NALMEFENE | Green | Alcohol dependence |
In line with NICE TA 325 |
| NALOXEGOL | Green | Opiod induced constipation |
In line with NICE TA345 |
| NALOXONE | Green Conditional | Palliative care in line with guidance. |
Conditional on recommendation from palliative care team. |
| NALOXONE nasal spray (Nyxoid®) (UPDATED) | Red | Opioid overdose |
Turning Point Only |
| NALTREXONE | Red | Pruritus in liver disease |
Unlicensed indication |
| NALTREXONE | Amber Simple | Opioid dependence |
To be initiated by specialists for maintenance treatment to help prevent relapse in opioid dependence. |
| NALTREXONE / BUPROPION M/R (Mysimba®) (NEW) | Black | Managing obesity |
NICE TA 494 not supported for managing obesity in adults |
| NAPROXEN / ESOMEPRAZOLE (Vimovo®) | Black | Osteoarthritis, RA & ankylosing spondylitis | |
| NARSOPLIMAB (NEW) | Red | IgA Nephropathy | |
| NATALIZUMAB | Red | Rapidly evolving relapsing-remitting multiple sclerosis | |
| Natamycin 5% eye drops | Red | Fungal keratitis (moulds only) | |
| NEBIVOLOL | Green | Hypertension |
Black for all other indications |
| NEBIVOLOL | Black | All indications excluding hypertension (Green) | |
| NELFINAVIR | Black | ||
| NETUPITANT/PALONOSETRON capsules (Akynzeo®) | Black | Prevention of nausea and vomiting associated with chemotherapy |
Not yet reviewed |
| NEVIRAPINE | Red | ||
| NILOTINIB | Red | ||
| NINTEDANIB (Ofev®) | Red | Idiopathic Pulmonary Fibrosis |
In line with NICE TA 379 |
| NINTEDANIB (Vargatef®) | Black | Lung cancer |
Not yet reviewed |
| NONACOG BETA PEGOL (Refixia®) (NEW) | Black | Haemophilia B |
Not yet reviewed. |
| NUVARING® | Green | Contraception | |
| OBETICHOLIC ACID | Red | Primary Biliary cholangitis |
In line with NICE TA 443 |
| OCRELIZUMAB (NEW) | Red | Relapsing-remitting multiple sclerosis |
In line with NICE TA 533 Implementation date 25th October 2018 |
| OCRELIZUMAB (NEW) | Red | Primary progressive multiple sclerosis |
In line with NICE TA585 |
| OCRIPLASMIN INJECTION (Jetrea®) | Red | Vitreomacular traction | |
| OCTREOTIDE | Red | Acromegaly |
New patients only |
| OCTREOTIDE | Red | GEP tumours and post-pancreatic surgery | |
| OCTREOTIDE | Green Conditional | Palliative care in line with guidance |
Conditional on recommendation from palliative care team. |
| OLANZAPINE | Green Conditional | Palliative care in line with guidance |
Conditional on recommendation from palliative care team. |
| OLANZAPINE Oral | Amber Full SCA | Schizophrenia. Combination therapy for mania. Preventing recurrence in bipolar disorder. Monotherapy for mania. Control of agitation and disturbed behaviour in schizophrenia or mania. Personality disorder. | |
| OLANZAPINE PAMOATE MONOHYDRATE (Zypadhera®) | Red | Schizophrenia |
Requires case by case consideration by Prescribing Group |
| OLMESARTAN/AMLODIPINE/HYDROCHLOROTHIAZIDE (Sevikar HCT) | Black | Non-adherence due to polypharmacy | |
| OLODATEROL INHALER | Black | COPD |
Not yet reviewed |
| OLOPATADINE | Green | Hay fever | |
| OMALIZUMAB | Red | Asthma |
In line with NICE TA 278 |
| OMALIZUMAB | Red | Chronic spontaneous urticaria | |
| OMBITASVIR/PARAPREVIR/RITONAVIR (Viekirax®) | Red | Hepatitis C |
In line with NICE TA 365 (with or without dasabuvir) |
| OMEGA-3 ACID ETHYL ESTERS (Dualtis®) | Black | Secondary prevention of MI, hypertriglyceridaemia |
Not yet reviewed |
| OMEGA-3 ACID ETHYL ESTERS (Omacor®) | Amber Simple | Hypertriglyceridaemia | |
| OMEGA-3 ACID ETHYL ESTERS (Omacor®) | Black | Secondary prevention of MI |
Contains Omega-3 acid ethyl esters |
| ONDANSETRON (UPDATED) | Green | Nausea |
Further information when used for palliative care can be found in the Palliative Care Prescribing Guide |
| OPICAPONE capsules (Ongentys®) | Black | Parkinson's disease |
Not yet reviewed |
| ORLISTAT | Green | ||
| OSIMERTINIB (Tagrisso®) | Black | Non-small-cell lung cancer | |
| OSPEMIFENE (Senshio®) (NEW) | Black | Vulvar and vaginal atrophy in post-menopausal women |
Not yet reviewed |
| OSVAREN® (previously known as REPHOREN®) | Amber Simple | Hyperphosphataemia | |
| OXYBUPROCAINE HYDROCORTISONE | Red | Local anaesthetic | |
| OXYBUTYNIN patch | Green | Symptomatic treatment of urge incontinence in unstable bladder |
For use only in patients who cannot take oral medication See Overactive bladder pathway |
| OXYCODONE / NALOXONE (Targinact®) | Amber Simple | Severe pain in patients with opioid-induced bowel dysfunction | |
| OXYCODONE HYDROCHLORIDE / NALOXONE (combination product) prolonged release tablet (Targinact®) | Black | Post colorectal surgery |
Reviewed by TAS – No evidence to support use for this indication. |
| PALIPERIDONE PALMITATE Long-Acting Injection | Amber Full SCA | Maintenance in schizophrenia in patients previously responsive to risperidone. | |
| PALIVIZUMAB | Red | ||
| PALONOSETRON | Black | Nausea and vomiting with chemotherapy | |
| PARATHYROID HORMONE (Natpar®) (UPDATED) | Red | Post-trial continuation of treatment of chronic hypoparathyroidism when standard therapy alone is inadequate. | |
| PARAVIT CF® (NEW) | Amber Simple | Vitamin Supplement for paediatric and adult patients with cystic fibrosis | |
| PARECOXIB(Dynastat ®) (NEW) | Amber Simple | Inflammatory pain associated with cancer or other palliative conditions | |
| PARICALCITOL | Black | Secondary hyperparathyroidism in renal failure | |
| PASIREOTIDE subcutaneous injection (Signifor®) | Black | Cushing’s disease |
Not yet reviewed |
| PATIROMER (Veltassa®) | Black | ||
| PATISIRAN (Onpattro®) (NEW) | Black | Hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy |
Not yet reviewed |
| PAZOPANIB | Red | ||
| PEGLOTICASE | Black | Gout |
Not supported by NICE |
| PENICILLAMINE | Red | Wilson's disease | |
| PENICILLAMINE | Amber Full SCA | Rheumatoid arthritis | |
| PENTHROX® (NEW) | Red | Emergency relief of moderate to severe pain in conscious adults |
Emergency department use only |
| PENTOSAN POLYSULFATE SODIUM (Elmiron®) (UPDATED) | Red | Bladder pain syndrome characterised by either glomerulations or Hunner’s lesions |
In line with NICE TA610 |
| PERAMPANEL (Fycompa®) | Amber Simple | Refractory epilepsy | |
| PERGOLIDE | Amber Simple | Parkinson's disease |
Click on drug name for further details |
| PIMECROLIMUS cream | Green | Dermatitis | |
| PIRFENIDONE (Esbriet®) (UPDATED) | Red | For Idiopathic pulmonary fibrosis |
In line with NICE TA 504 (Replaces NICE TA 282) |
| PITOLISANT (Wakix®) (NEW) | Amber Simple | Narcolepsy | |
| PITRESSIN | Red | Myomectomy | |
| PIVMECILLINAM | Green | Extended Spectrum Beta Lactamase (ESBL) Urinary Tract Infection (UTI) |
UTI in line with Primary care Multi-resistant lower UTI Guidance |
| PLASMA-LYTE 148 & 5% GLUCOSE solution for infusion (NEW) | Red | Source of water, electrolyte and calories or as a alkalinising agent | |
| POLIHEXANIDE 0.02% eye drops | Red | ||
| Pollinex Quattro | Black | Severe hayfever caused by tree & grass pollen | |
| POMALIDOMIDE | Red | ||
| PONATINIB | Red | ||
| POSACONAZOLE | Red | Severe fungal infections | |
| PRAMIPEXOLE | Amber Full SCA | Parkinson's Disease, Restless Legs Syndrome and other limb movement disorders |
Click on drug name for further details |
| PRASTERONE PESSARY (Intrarosa®) (UPDATED) | Amber Simple | Vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms | |
| PRASUGREL | Amber Simple | ACS where immediate primary percutaneous coronary intervention for ST segment-elevation MI is necessary or stent thrombosis has occurred during clopidogrel treatment. |
Excludes pts over 75yrs and /or weight less than 60kg Duration summary for primary care |
| PREGABALIN | Green | Neuropathic pain |
To be used in conjunction with Neuropathic Pain Guidelines |
| PREGABALIN | Amber Simple | Refractory epilepsy | |
| PREGABALIN | Amber Simple | Generalised anxiety disorder | |
| PRILOCAINE | Red | Spinal Anaesthesia | |
| PRO-SIL® | Amber Simple | Hypertrophic Scars |
Includes: Kelocote®, Pro-Sil®, Cica-Care®, Advasil Conform® and Mepiform® |
| PROCARBAZINE | Red | ||
| PROGESTERONE PESSARIES (Cyclogest®) | Amber Simple | Maintenance of pregnancy following IVF or when there is a risk of pre-term delivery | |
| PROXYMETACAINE HYDROCHLORIDE | Red | Local anaesthetic | |
| PRUCALOPRIDE (UPDATED) | Green | Chronic refractory constipation | |
| PYRIDOSTIGMINE | Amber Simple | Myasthenia gravis |
Includes sustained release formulation (Mestinon Timespan). |
| QLAIRA® | Black | Contraception |
Not approved by local committee |
| QUETIAPINE | Amber Full SCA | Schizophrenia. Mania (either alone or in combination with mood stabilisers). Depression in bipolar disorder. Adjunctive treatment in major depressive disorder. Personality disorder. | |
| QUETIAPINE | Green Conditional | Palliative care in line with guidance. |
Conditional on recommendation from palliative care team. |
| QUINAGOLIDE | Amber Simple | Hyperprolactinaemia | |
| RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN (Thymoglobuline®) (NEW) | Red | Immunosuppressive therapy for Kidney Transplant in Adults and Children/Young People |
In line with NICE TA 481, NICE TA 482 |
| RACECADOTRIL (Hidrasec®) | Black | Diarrhoea | |
| RALOXIFENE (NEW) | Amber Simple | Off label chemoprevention to reduce incidence of breast cancer. |
Use in line with NICE CG 164 |
| RALOXIFENE (NEW) | Black | Primary prevention of osteoporotic fragility in menopausal women |
Not recommended in NICE TA 160 |
| RALOXIFENE (NEW) | Amber Simple | Secondary prevention of osteoporotic fragility in menopausal women |
In line with NICE TA 161 |
| RALTEGRAVIR | Red | Multi-resistant HIV, Needlestick injury | |
| RANIBIZUMAB (Lucentis®) | Red | Age-related macular degeneration, diabetic macular oedema, retinal vein occlusion | |
| RANOLAZINE | Green | Chronic stable angina |
In line with NICE CG 126 |
| RASAGILINE | Amber Simple | Parkinson's disease |
Click on drug name for further details
|
| RAVULIZUMAB (Ultomiris®) (NEW) | Black | Paroxysmal nocturnal haemoglobinuria |
Not yet reviewed |
| REGORAFENIB | Red | ||
| REPAGLINIDE | Green | ||
| RESLIZUMAB | Red | Severe Eosinophilic Asthma |
In line with NICE TA 479 |
| RESPERATE device | Black | Hypertension |
Reviewed by Dr A. Stanley, Hypertension Clinic |
| RETAPAMULIN | Black | Bacterial skin infections | |
| RETIGABINE | Red | Treatment resistant epilepsy | |
| RIBAVIRIN | Red | ||
| RIBOFLAVIN eye drops | Red | Peri-operative use during collagen cross linkage | |
| RIFAMPICIN/ISONIAZID/PYRAZINAMIDE/ETHAMBUTOL (Voractiv) | Red | Tuberculosis | |
| RIFAPENTINE (Priftin®) (NEW) | Red | Latent TB | |
| RIFAXIMIN | Amber Simple | Reduction in recurrence of hepatic encaphalopathy | |
| RIFAXIMIN | Black | Traveller's diarrhoea | |
| RILPIVIRINE | Red | ||
| RILUZOLE | Amber Full SCA | Amylotrophic lateral sclerosis form of motor neurone disease | |
| RIMEXOLONE | Red | ||
| RIOCIGUAT | Black | Pulmonary hypertension | |
| RISANKIZUMAB (Skyrizi®) (UPDATED) | Red | Moderate to severe plaque psoriasis |
In line with NICE TA596 |
| RISEDRONATE SODIUM | Green | Osteoporosis |
In line with NICE TA 464 |
| RISPERIDONE LONG-ACTING INJECTION (Risperdal Consta®) | Amber Full SCA | Schizophrenia and other psychoses in patients tolerant to oral risperidone. | |
| RISPERIDONE Oral | Amber Full SCA | Acute and chronic psychoses. Mania. Short term (up to 6 weeks) of persistent aggression in patients with moderate to severe AD. Short term (up to 6 weeks) treatment of persistent aggression in conduct disorder. Personality disorder. | |
| RITONAVIR | Red | ||
| RITUXIMAB | Red | Immunobullous diseases |
In line with NHS England policy |
| RITUXIMAB | Red | Lymphoma, Rheumatoid arthritis | |
| RIVAROXABAN | Amber Simple | Cardioversion | |
| RIVAROXABAN | Red | ACS |
In line with NICE TA 335 |
| RIVAROXABAN | Green | Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation |
Use in line with |
| RIVAROXABAN | Black | Prevention of VTE in adults undergoing hip or knee replacement | |
| RIVAROXABAN | Amber Simple | Treatment and secondary prevention of DVT and PE |
In line with NICE TA 261 or NICE TA 287 |
| RIVAROXABAN (Xarelto®) (NEW) | Amber Simple | Preventing atherothrombotic events in people with coronary or peripheral artery disease |
In line with NICE TA607 |
| RIVASTIGMINE (UPDATED) | Amber Simple | Alzheimer's disease |
in line with NICE NG 97 Change in traffic light status from 1st October 2018 |
| ROFLUMILAST | Amber Simple | COPD |
In line with NICE TA 461 |
| ROMIPLOSTIM (Nplate®) | Red | Chronic immune (idiopathic) thrombocytopenic purpura (ITP) |
Use in line with NICE TA 221 |
| ROMOSOZUMAB SOLUTION FOR INJECTION (Evenity®) (NEW) | Black | Severe osteoporosis in postmenopausal women at high risk of fracture |
Not yet reviewed |
| ROPINIROLE | Amber Simple | Parkinson's Disease, Restless Legs Syndrome and other limb movement disorders |
Click on drug name for further details |
| ROPIVACAINE 2 mg/ml solution for infusion dispensed via ReadyfusOR® infusion pump (NEW) | Black | For acute post operative pain in adults | |
| ROSIGLITAZONE (Avandia®, Avandamet®) | Black | Withdrawn | |
| ROSUVASTATIN | Green | Hypercholesterolaemia | |
| ROTIGOTINE | Amber Full SCA | Parkinson's disease, Restless Legs Syndrome and other limb movement disorders |
Click on drug name for further details |
| RUFINAMIDE | Amber Simple | Lennox-Gastaut syndrome in patients aged over 4 years | |
| RUXOLITINIB | Red | ||
| SACUBITRIL / VALSARTAN (Entresto®) | Amber Full SCA | Heart failure | |
| SAFINAMIDE (Xadago®) (UPDATED) | Amber Simple | Parkinson’s Disease | |
| SAQUINAVIR | Red | ||
| SARILUMAB (NEW) | Red | Moderate to Severe Rheumatoid Arthritis |
In line with NICE TA 485 |
| SATIVEX | Black | Treatment of spasticity associated with Multiple Sclerosis | |
| SAXAGLIPTIN (Onglyza®) | Green | Type 2 Diabetes. |
Non-formulary choice. |
| SAXAGLIPTIN / METFORMIN (Komboglyze®) | Black | Type 2 Diabetes | |
| SECUKINUMAB | Red | Psoriatic arthritis |
In line with NICE TA 445 |
| SECUKINUMAB | Red | Psoriasis |
In line with NICE TA 350 |
| SECUKINUMAB | Red | Ankylosing spondylitis. |
Use in line with NICE TA 407 |
| SELEGILINE | Amber Simple | Parkinson's disease |
Click on drug name for further details |
| SELEXIPAG (Uptravi®) | Black | Pulmonary arterial hypertension |
Not yet reviewed |
| SEMAGLUTIDE (Ozempic®) (UPDATED) | Green Conditional | GLP 1 analogue |
Conditional on prescriber being competent to select appropriate patients. |
| SERTRALINE (UPDATED) | Amber Simple | Mental health indications as per the children’s BNF for children and young people | |
| SEVELAMER | Amber Simple | Hyperphosphataemia | |
| SILDENAFIL | Red | Pulmonary arterial hypertension | |
| SILDENAFIL ORAL SUSPENSION (Revatio®) | Black |
Pulmonary artery hypertension |
|
| SILICONE GEL / GEL SHEETS | Amber Simple | Hypertrophic Scars |
Includes: Kelocote®, Pro-Sil®, Cica-Care®, Advasil Conform® and Mepiform® |
| SIMEPREVIR | Red | Hepatitis C | |
| SIPONIMOD FUMARIC ACID (Mayzent®) (NEW) | Black | Secondary progressive multiple sclerosis with active disease |
Not yet reviewed |
| SIROLIMUS (NEW) | Red | Immunosuppression post renal transplant | |
| SIROLIMUS (UPDATED) | Amber Full SCA | Immunosuppression post renal transplant |
Exception agreed to red status: Full shared care to allow GPs to continue supplying to historical patients still on shared care where appropriate for patient and the GP agrees. Full SCA |
| SIROLIMUS GEL (NEW) | Red | Angiofibromas associated with tuberous sclerosis complex | |
| SITAGLIPTIN | Green | Type 2 diabetes |
In line with NICE CG 87 |
| SITAGLIPTIN / METFORMIN (Janumet®) | Black | Type 2 diabetes | |
| SODIUM CHLORIDE 5% preservative free eye drops or 5% ointment | Amber Simple | Ocular lubricants | |
| SODIUM CITRATE 10.11% eye drops | Red | ||
| SODIUM HYALURONATE, CO-ENZYME Q10 AND VITAMIN E COMBINATION EYE DROP (VisuXl ®) (NEW) | Green | Severe dry eye and corneal healing post-surgery | |
| SODIUM OXYBATE | Amber Simple | Treatment of cataplexy associated with narcolepsy | |
| SODIUM VALPROATE SR (Episenta®) | Black | Epilepsy |
Not approved by local committee |
| SODIUM ZIRCONIUM CYCLOSILICATE (Lokelma®) (UPDATED) | Red | Hyperkalaemia |
In line with NICE TA599. Implementation date 4th December 2019. |
| SOFOSBUVIR | Red | Hepatitis C | |
| SOFOSBUVIR/VELPATASVIR (Epclusa®) | Red | Hepatitis C |
In line with NICE TA 430 |
| SOFOSBUVIR–VELPATASVIR-VOXILAPREVIR (Vosevi®) (NEW) | Red | For Chronic hepatitis C |
IMPLEMENTATION from 21st May 2018 |
| SOLIFENACIN | Green | Urinary incontinence | |
| SOLIFENACIN / TAMSULOSIN (Vesomni®) | Green | Benign prostatic hyperplasia |
In line with Male LUTS Pathway |
| SOLRIAMFETOL (Sunosi®) (NEW) | Black | Improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with narcolepsy |
Not yet reviewed |
| SOMATROPIN (Growth Hormone) | Red | Growth disorders |
New patients supplied through healthcare at home |
| SORAFENIB | Red | ||
| SOYBEAN OIL EYE DROPS (Emustil®) | Black | Ocular lubricant |
Not yet reviewed |
| SPIRONOLACTONE | Amber Full SCA | Heart failure and hypertension in infants and children | |
| STAVUDINE | Black | ||
| STRIBILD | Red | HIV | |
| SUCROFERRIC OXYHYDROXIDE (Velphoro®) | Red | Treatment/prevention of hyperphosphataemia of chronic kidney disease | |
| SUFENTANIL (Zalviso®) sublingual tablets | Black | Acute post-operative pain |
Not yet reviewed |
| SUGAMMADEX | Red | Reversal of neuromuscular blockade |
Emergency use only. |
| SULFASALAZINE | Amber Full SCA | Rheumatological disease | |
| SULFASALAZINE | Red | Inflammatory Bowel Disease in Paediatrics | |
| SULFASALAZINE ORAL & RECTAL | Amber Full SCA | Ulcerative colitis and Crohn's disease |
Shared care request is mandatory |
| SULPIRIDE | Green Conditional | Schizophrenia |
If for use in schizophrenia or psychoses–to be initiated after discussion with specialist |
| SUNITINIB | Red | ||
| SYMTUZA® (NEW) | Red | Combination HIV treatment |
As part of NHS England Clinical Commissioning policy |
| SYNVISC® | Black | Black in ALL indications except for Pain relief in osteoarthritis of shoulder joint (RED) | |
| SYNVISC® | Red | Pain relief in oesteoarthritis of shoulder joint. | |
| SYSTANE® ULTRA preservative free eye drops | Amber Simple | Ocular lubricants |
Use in line with guidance |
| TACROLIMUS capsules (Adoport®, Prograf® or Modigraf®) (UPDATED) | Amber Full SCA | Immunosuppression post renal transplant - prescribe by brand name only as different brands are not interchangeable |
Exception agreed to red status: Full shared care to allow GPs to continue supplying to historical patients still on shared care where appropriate for patient and the GP agrees. |
| TACROLIMUS capsules (Adoport®, Prograf® or Modigraf®) (NEW) | Red | Immunosuppression post renal transplant - prescribe by brand name only as different brands are not interchangeable | |
| TACROLIMUS capsules (Advagraf®) | Black | Immunosuppression |
Modified-release |
| TACROLIMUS ointment | Green | Dermatitis | |
| TACROLIMUS SR (Envarsus®) | Red | Prophylaxis of transplant rejection in adult kidney transplants | |
| TADALAFIL | Black | Benign prostatic hyperplasia | |
| TADALAFIL | Green | Erectile dysfunction |
For patients who have not responded to sildenafil or to vardenafil. Daily dose not supported |
| TADALAFIL (Adcirca®) | Black | Pulmonary arterial hypertension | |
| TAFAMIDIS (NEW) | Red | Transthyretin amyloidosis with cardiomyopathy as part of EAMS | |
| TAFLUPROST/TIMOLOL preservative free eye drops (Taptiqom®) | Black | Glaucoma |
Not yet reviewed |
| TAMOXIFEN | Amber Simple | Treatment and prevention of breast cancer | |
| TAMSULOSIN capsules | Green | Benign prostatic hypertrophy | |
| TAMSULOSIN tablets | Black | Benign prostatic hypertrophy | |
| TAPENTADOL immediate release | Black | Acute pain | |
| TAPENTADOL sustained release | Amber Simple | Moderate to severe chronic pain (pain clinic recommendation only) | |
| TEDIZOLID PHOSPHATE tablets and infusion (Sivextro®) | Black | Skin infection |
Not yet reviewed |
| TEDUGLUTIDE injection | Black | Short bowel syndrome |
Not yet reviewed |
| TEGAFUR / GIMERACIL / OTERACIL | Red | ||
| TEGAFUR / URACIL | Red | ||
| TEICOPLANIN | Green | Cellulitis (in primary care) |
To be used in conjunction with the Primary Care Cellulitis Pathway |
| TEICOPLANIN | Red | All indications except cellulitis in primary care | |
| TEMOZOLOMIDE | Red | ||
| TENOFOVIR | Red | ||
| TENOFOVIR / EMTRICITABINE (Truvada®) | Red | ||
| TENOFOVIR ALAFENAMIDE (Vemlidy®) | Black | Hepatitis B |
New formulation |
| TERIFLUNOMIDE | Red | Multiple sclerosis |
In line with NICE TA 303 |
| TERIPARATIDE (UPDATED) | Red | Osteoporosis in men and women | |
| TESTOSTERONE | Amber Full SCA | Replacement therapy in children and adolescents | |
| TESTOSTERONE | Amber Full SCA | Adult male hypogonadism |
|
| TESTOSTERONE | Amber Full SCA | Gender reassignment |
To be used and monitored in line with guidance/written information from specialist centre consultant/team (nearest clinic is in Nottinghamshire*) |
| TESTOSTERONE buccal | Black | Male hypogonadism | |
| TESTOSTERONE GEL (Tostran ®) (UPDATED) | Amber Simple | Testosterone deficiency in menopausal women (unlicensed) |
Tostran brand only. As per NICE NG 23 |
| TESTOSTERONE Patches (Intrinsa®) | Black | Hypoactive sexual desire disorder in women |
Not approved by local committee |
| TEZACAFTOR AND IVACAFTOR (Symkevi ®) (NEW) | Red | Cystic Fibrosis | |
| THALIDOMIDE | Black | Multiple myeloma | |
| TICAGRELOR | Amber Simple | Troponin positive Acute Coronary Syndromes in NSTEMI patients |
Duration summary for primary care |
| TIGECYCLINE | Red | Skin and soft tissue infections | |
| TILDRAKIZUMAB (Ilumetri®) (NEW) | Red | Moderate to severe plaque psoriasis |
In line with NICE TA575 Implementation date 17th July 2019 |
| TIMOLOL LA Gel-Forming Eye Drops | Red | Small infantile haemangiomas |
In line with GOSH guidance |
| TIOGUANINE | Red | ||
| TIOTROPIUM (Braltus Zonda®) | Green | COPD |
Use in line with Leicestershire LAMA Prescribing Guide
|
| TIOTROPIUM (Spiriva HandiHaler® or Spiriva Respimat®) | Green | COPD | |
| TIOTROPIUM (Spiriva Respimat®) | Amber Simple | Asthma | |
| TIOTROPIUM/OLODATEROL (Spiolto Respimat®) | Green | COPD |
NEW LABA/LAMA combination product – to be used in line with updated COPD Guidelines |
| TIPRANAVIR | Red | HIV infection | |
| TIPRANAVIR | Red | ||
| TIVOZANIB (Fotivda®) (NEW) | Black | Advanced renal cell carcinoma |
Not yet reviewed |
| TIZANIDINE | Amber Full SCA | MS spasticity |
SCA to be developed. Existing primary care prescribing to continue. |
| TOBRAMYCIN (Vantobra®) | Black | Chronic pulmonary infection due to Pseudomonas aeruginosa |
New formulation |
| TOBRAMYCIN inhalation | Red | Cystic fibrosis | |
| TOBRAMYCIN injection | Red | ||
| TOCILIZUMAB | Red | Juvenile idiopathic arthritis |
In line with NICE TA 373 |
| TOCILIZUMAB (NEW) | Red | Treating giant cell arteritis. |
In Line with NICE TA 518
|
| TOCILIZUMAB | Red | Rheumatoid arthritis |
In line with NICE Technology Appraisal TA247 Both the intraveneous and subcutaneous preparations are RED |
| TOCILIZUMAB (NEW) | Red | Adult onset stills disease |
Requested for UHL as part of NHS England commissioning policy. |
| TOCILIZUMAB (NEW) | Black | Treatment of chimeric antigen receptor induced cytokine release syndrome |
Not yet reviewed. |
| TOFACITINIB (NEW) | Red | Active psoriatic arthritis after inadequate response to DMARDS |
In line with NICE TA543 Implementation date 3rd January 2019 |
| TOFACITINIB (NEW) | Red | Moderately to severely active ulcerative colitis |
In line with NICE TA 547 Implementation date 28th February 2019 |
| TOFACITINIB (NEW) | Red | Moderate to Severe Rheumatoid Arthritis |
In line with NICE TA 480 |
| TOLCAPONE | Red | Parkinson's disease | |
| TOLVAPTAN (Jinarc®) | Red | Autosomal dominant polycystic kidney disease |
In line with NICE TA 358 |
| TOLVAPTAN (Samsca®) | Black | Hyponatraemia secondary to SIADH | |
| TOPIRAMATE | Green | Migraine | |
| TOPIRAMATE | Amber Simple | Epilepsy | |
| TOPOTECAN | Red | ||
| TRAMADOL | Green | Severe pain |
Including SR tablets |
| TRAMADOL HYDROCHLORIDE / DEXKETOPROFEN (Skudexa®) (NEW) | Black | Pain | |
| TRAMETINIB (Mekinist®) | Black | Melanoma |
Not yet reviewed |
| TREOSULFAN | Red | ||
| TRICHLOROACETIC ACID (NEW) | Red | Resolution of cyst in enucleated socket | |
| TRICLABENDAZOLE (NEW) | Red | Hepatic fascioliasis |
Approved by the Antimicrobial Working Party |
| TRIENTINE | Red | Wilson's disease | |
| TRIFLURIDINE / TIPIRACIL (Lonsurf®) | Black |
Not yet reviewed |
|
| TRIFLURIDINE 1% eye drops | Red | ||
| TRIPLE BROMIDES | Black | Intractable epileptic seizures |
Not approved by local committee |
| TRIPTORELIN | Amber Simple | Endometriosis, uterine fibroids | |
| TRIPTORELIN | Amber Simple | Precocious puberty | |
| TRIPTORELIN | Green | Prostatic carcinoma |
GP can give first injection to patients in whom anti-androgen treatment has been started by secondary care clinician. |
| TROSPIUM (immediate release) | Green | Urinary frequency, urgency and incontinence | |
| TROSPIUM XL | Black | Urinary incontinence | |
| TYPICAL ORAL ANTIPSYCHOTICS | Green Conditional | See individual entries |
If used for schizophrenia or psychoses to be initiated only after diagnosis and advice to use typical antipsychotic has been discussed with specialist (green for other licensed indications) |
| UBIQUINONE Q10 | Black | Statin-induced myopathy |
Not approved by local committee |
| ULIPRISTAL ACETATE (ellaOne®) | Green | Emergency contraception |
To be taken from between 72 hours (3 days) to 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure. Within the first 72 hours use Levonelle®. (Levonelle® 1500 is available on prescription. Levonelle One Step® can be sold to women over the age of 16 years)
|
| ULIPRISTAL ACETATE (Esmya ®) (UPDATED) | Black | Uterine fibroids |
In line with MHRA alert March 2020 regarding risks of liver injury. |
| UMECLIDINIUM / VILANTEROL inhaler (Anoro Ellipta®) | Black | COPD |
Not yet reviewed |
| UMECLIDINIUM inhaler (Incruse Ellipta®) | Black | COPD |
Not yet reviewed |
| UPADACITINIB (RINVOQ®) (NEW) | Black | Moderate to severe active rheumatoid arthritis, responded inadequately to, or who are intolerant to one or more DMARDs. |
Not yet reviewed |
| UROFOLLITROPIN(Fostimon®) | Red | IVF | |
| USTEKINUMAB | Red | Plaque psoriasis |
Supported by NICE |
| USTEKINUMAB | Red | Crohns |
In line with NICE TA 456 |
| USTEKINUMAB | Red | Psoriatic arthritis | |
| USTEKINUMAB | Red | Plaque psoriasis in children |
In line with NICE TA 455 |
| USTEKINUMAB (Stelara®) (NEW) | Black | Ulcerative Colitis |
Not yet reviewed |
| USTEKINUMAB (Stelara®) | Red | Psoriasis | |
| VALGANCICLOVIR (Valcyte®) | Red | Cytomegalovirus retinitis | |
| VALPROATE SEMISODIUM (Depakote®) | Amber Simple | Mania in bipolar disorder | |
| VALSARTAN / AMLODIPINE (Exforge®) | Black | Hypertension |
Not approved by local committee |
| VANDETANIB | Red | ||
| VARENICLINE | Green | Smoking cessation |
Alternative option to NRT or buproprion subject to patient using accredited smoking cessation services |
| VEDOLIZUMAB | Red | Ulcerative colitis | |
| VEMURAFENIB | Red | ||
| VENLAFAXINE | Green | Depression - low dose (<300mg) | |
| VENLAFAXINE | Amber Full SCA | Treatment resistant depression - high dose (≥300mg) | |
| VILDAGLIPTIN | Black | Type 2 diabetes | |
| VILDAGLIPTIN / METFORMIN (Eucreas®) | Black | Type 2 diabetes | |
| VIMOVO® (esomeprazole +naproxen) | Black | Rheumatoid arthritis, osteoarthritis and ankylosing spondylitis | |
| VINORELBINE | Red | ||
| VISMODEGIB | Red | ||
| VITAMIN A CAPSULES (Phebra ®) (NEW) | Amber Simple | Severe Vitamin A deficiency due to bariatric surgery or malabsorptive disorder | |
| VITAMIN A IM INJECTION (NEW) | Red | Severe Vitamin A deficiency due to bariatric surgery or malabsorptive disorder where enteral routes are compromised | |
| VONICOG ALFA (Veyvondi®) (NEW) | Black | Von Willebrand disease |
Not yet reviewed |
| VORETIGENE NEPARVOVEC (Luxturna®) (NEW) | Black | Vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations |
Not yet reviewed |
| VORICONAZOLE | Red | All indications - High cost drug - use on microbiologist advice only | |
| VORTIOXETINE | Amber Simple | Major depressive disorder |
Third line option |
| VSL#3 (UPDATED) | Black | Probiotic | |
| YASMIN® | Green | Contraception |
NOTE: More expensive, with no evidence of significant advantages, compared to other similar OCs. |
| ZANAMIVIR SOLUTION FOR INFUSION (Dectova®) (NEW) | Red | Treatment of complicated and potentially life-threatening influenza | |
| ZICONOTIDE | Black | Severe chronic pain (intrathecal) | |
| ZIDOVUDINE | Red | ||
| ZOLENDRONIC ACID infusion | Red | Pagets disease & Osteoporosis | |
| ZONISAMIDE | Amber Simple | Refractory epilepsy | |
| ZOSTAVAX (Varicella zoster vaccine) | Black | Prevention of shingles and post-herpetic neuralgia. Live vaccine therefore NOT suitable for immunocompromised patients. Do not prescribe on FP10 (black through this route). |
Available centrally from 1st Sept 2013 for those aged 70 and 79 years |
| ZUCLOPENTHIXOL ACETATE (Clopixol Acuphase®) | Red | Short-term management of acute psychosis or mania |
Refer to Local Area Team letter May 2013 |
| ZUCLOPENTHIXOL DECANOATE (Clopixol® Depot and Clopixol® Conc.) | Amber Full SCA | Schizophrenia | |
| ZUCLOPENTHIXOL ORAL | Green Conditional | Schizophrenia and other psychoses |
If used for schizophrenia or psychoses to be initiated only after diagnosis and advice to use typical antipsychotic has been discussed with specialist |
Traffic Light Classifications
Black
Drugs not recommended for use in the Leicestershire Health Community because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.
All new drugs will be black until they have been through the appropriate approval process - then they will appear as a specific entry.
Red
Drugs which should be prescribed only by hospital specialists (clinical review by specialist as appropriate and annually as a minimum).
Amber Full SCA
Drugs which would initially be prescribed by a hospital specialist and then by a GP where full agreement to share the care of each specific patient has been reached under a LMSG Shared Care Agreement (SCA). Specific patient monitoring or intervention required.
Amber Simple
Drugs suitable to be initiated and prescribed in primary care only after specialist assessment and recommendation. A shared care agreement is not required.
Green Conditional
Drugs for which GPs are able to take full responsibility for prescribing and monitoring subject to specified conditions e.g. prescribing in line with agreed LMSG guidance or able to demonstrate suitable competence see comments under individual entries.
Green
Drugs for which GPs would normally take full responsibility for prescribing and monitoring. Drugs included in this list have been specifically considered by LMSG.